Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:proteasome inhibitor
go back to main search page
Accession:CHEBI:52726 term browser browse the term
Definition:A drug that blocks the action of proteasomes, cellular complexes that break down proteins.
Synonyms:related_synonym: proteasome inhibitors


show annotations for term's descendants           Sort by:
 
bortezomib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca2 ATP binding cassette subfamily A member 2 decreases expression ISO Bortezomib results in decreased expression of ABCA2 mRNA CTD PMID:20977926 NCBI chr 3:2,648,787...2,668,770
Ensembl chr 3:2,648,885...2,668,809
JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
decreases expression
decreases activity
ISO ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein]
[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]
Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA
Bortezomib results in decreased activity of ABCB1 protein
CTD PMID:25576094, PMID:30482226 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 decreases expression ISO Bortezomib results in decreased expression of ABCC1 mRNA CTD PMID:20977926 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO Bortezomib results in increased expression of ABCC2 mRNA CTD PMID:21215737 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 decreases expression ISO Bortezomib results in decreased expression of ABCC4 mRNA CTD PMID:20977926 NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
JBrowse link
G Abhd16a abhydrolase domain containing 16A, phospholipase increases expression ISO Bortezomib results in increased expression of ABHD16A mRNA CTD PMID:20977926 NCBI chr20:5,080,070...5,094,935
Ensembl chr20:5,080,070...5,094,935
JBrowse link
G Abhd2 abhydrolase domain containing 2, acylglycerol lipase increases expression ISO Bortezomib results in increased expression of ABHD2 mRNA CTD PMID:20977926 NCBI chr 1:140,998,240...141,087,405
Ensembl chr 1:140,998,240...141,087,405
JBrowse link
G Abi1 abl-interactor 1 increases expression ISO Bortezomib results in increased expression of ABI1 mRNA CTD PMID:20977926 NCBI chr17:89,951,662...90,033,334
Ensembl chr17:89,951,752...90,033,328
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein] CTD PMID:15039284, PMID:17495969, PMID:21195056 NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
JBrowse link
G Ace angiotensin I converting enzyme multiple interactions ISO [Butyrates co-treated with Bortezomib] results in increased activity of ACE protein mutant form CTD PMID:20454656 NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
JBrowse link
G Acot7 acyl-CoA thioesterase 7 decreases expression ISO Bortezomib results in decreased expression of ACOT7 mRNA CTD PMID:20977926 NCBI chr 5:169,357,582...169,450,215
Ensembl chr 5:169,357,517...169,450,219
JBrowse link
G Adam10 ADAM metallopeptidase domain 10 decreases expression ISO Bortezomib results in decreased expression of ADAM10 mRNA CTD PMID:20977926 NCBI chr 8:77,107,355...77,237,483
Ensembl chr 8:77,107,536...77,237,483
JBrowse link
G Adm adrenomedullin multiple interactions
decreases expression
ISO Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of ADM mRNA]
Bortezomib results in decreased expression of ADM mRNA
CTD PMID:20471514 NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
JBrowse link
G Aff1 AF4/FMR2 family, member 1 increases expression ISO Bortezomib results in increased expression of AFF1 mRNA CTD PMID:20977926 NCBI chr14:7,222,883...7,384,916
Ensembl chr14:7,226,586...7,384,876
JBrowse link
G Aff4 AF4/FMR2 family, member 4 increases expression ISO Bortezomib results in increased expression of AFF4 mRNA CTD PMID:20977926 NCBI chr10:38,692,167...38,773,021
Ensembl chr10:38,692,211...38,773,021
JBrowse link
G Agk acylglycerol kinase decreases expression ISO Bortezomib results in decreased expression of AGK mRNA CTD PMID:20977926 NCBI chr 4:68,483,345...68,561,518
Ensembl chr 4:68,483,320...68,560,801
JBrowse link
G Agrn agrin decreases expression ISO Bortezomib results in decreased expression of AGRN mRNA CTD PMID:20977926 NCBI chr 5:173,589,910...173,622,813
Ensembl chr 5:173,589,819...173,622,645
JBrowse link
G Agtpbp1 ATP/GTP binding protein 1 increases expression ISO Bortezomib results in increased expression of AGTPBP1 mRNA CTD PMID:20977926 NCBI chr17:5,510,009...5,614,416
Ensembl chr17:5,511,385...5,614,435
JBrowse link
G Agtrap angiotensin II receptor-associated protein decreases expression ISO Bortezomib results in decreased expression of AGTRAP mRNA CTD PMID:20977926 NCBI chr 5:164,888,069...164,898,387
Ensembl chr 5:164,886,813...164,898,420
JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 affects localization
multiple interactions
ISO Bortezomib affects the localization of AIFM1 protein
[Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein
CTD PMID:12893773, PMID:16024631 NCBI chr  X:135,304,063...135,343,062
Ensembl chr  X:135,304,066...135,343,087
JBrowse link
G Aifm2 apoptosis inducing factor, mitochondria associated 2 increases expression ISO Bortezomib results in increased expression of AIFM2 mRNA CTD PMID:20977926 NCBI chr20:31,329,047...31,353,548
Ensembl chr20:31,339,787...31,352,906
JBrowse link
G Aim2 absent in melanoma 2 increases expression ISO Bortezomib results in increased expression of AIM2 mRNA CTD PMID:20977926 NCBI chr13:91,919,834...91,963,080
Ensembl chr13:91,954,138...91,962,588
JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B increases expression ISO Bortezomib results in increased expression of AKR1B1 mRNA; Bortezomib results in increased expression of AKR1B1 protein CTD PMID:21215737 NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 increases expression ISO Bortezomib results in increased expression of AKR1B10 mRNA; Bortezomib results in increased expression of AKR1B10 protein CTD PMID:21215737 NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
JBrowse link
G Akr1b8 aldo-keto reductase family 1, member B8 increases expression EXP Bortezomib results in increased expression of AKR1B8 mRNA CTD PMID:20830808 NCBI chr 4:61,772,064...61,784,637
Ensembl chr 4:61,771,970...61,828,657
JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 affects expression ISO Bortezomib affects the expression of AKR1C2 mRNA CTD PMID:21215737 NCBI chr17:69,388,337...69,435,160
Ensembl chr17:69,388,335...69,404,341
JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 increases expression ISO Bortezomib results in increased expression of AKR1C3 mRNA CTD PMID:21215737 NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA CTD PMID:25522274 NCBI chr 5:157,759,448...157,768,473
Ensembl chr 5:157,759,416...157,768,471
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases expression
decreases activity
ISO [alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form]
Bortezomib results in decreased activity of AKT1 protein
CTD PMID:15039284, PMID:15781649, PMID:16118318, PMID:16985072, PMID:18445700, PMID:18701494, PMID:19261616, PMID:19457607, PMID:20701607, PMID:21472287 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Aldh18a1 aldehyde dehydrogenase 18 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH18A1 mRNA CTD PMID:20977926 NCBI chr 1:259,641,673...259,674,521
Ensembl chr 1:259,641,676...259,674,425
Ensembl chr 1:259,641,676...259,674,425
JBrowse link
G Aldh5a1 aldehyde dehydrogenase 5 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH5A1 mRNA CTD PMID:20977926 NCBI chr17:42,133,076...42,159,413
Ensembl chr17:42,133,076...42,159,413
JBrowse link
G Aldh6a1 aldehyde dehydrogenase 6 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH6A1 mRNA CTD PMID:20977926 NCBI chr 6:108,146,552...108,167,185
Ensembl chr 6:108,146,582...108,167,185
JBrowse link
G Alox12 arachidonate 12-lipoxygenase, 12S type increases response to substance ISO ALOX12 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr10:56,851,734...56,864,049
Ensembl chr10:56,851,734...56,864,005
JBrowse link
G Anapc11 anaphase promoting complex subunit 11 decreases expression ISO Bortezomib results in decreased expression of ANAPC11 mRNA CTD PMID:17659339 NCBI chr10:109,774,779...109,785,877
Ensembl chr10:109,774,878...109,785,877
JBrowse link
G Anapc5 anaphase-promoting complex subunit 5 decreases expression
increases expression
ISO Bortezomib results in decreased expression of ANAPC5 mRNA
Bortezomib results in increased expression of ANAPC5 mRNA
CTD PMID:17895889, PMID:20977926 NCBI chr12:39,209,134...39,242,696
Ensembl chr12:39,209,129...39,242,690
JBrowse link
G Ankrd9 ankyrin repeat domain 9 increases expression ISO Bortezomib results in increased expression of ANKRD9 mRNA CTD PMID:20977926 NCBI chr 6:135,409,698...135,412,552
Ensembl chr 6:135,410,030...135,412,312
JBrowse link
G Ano10 anoctamin 10 increases expression ISO Bortezomib results in increased expression of ANO10 mRNA CTD PMID:20977926 NCBI chr 8:130,812,941...130,931,021
Ensembl chr 8:130,813,214...130,930,990
JBrowse link
G Ap1s1 adaptor related protein complex 1 subunit sigma 1 decreases expression ISO Bortezomib results in decreased expression of AP1S1 mRNA CTD PMID:20977926 NCBI chr12:22,665,128...22,676,079
Ensembl chr12:22,665,112...22,676,075
JBrowse link
G Ap2a1 adaptor related protein complex 2 subunit alpha 1 decreases expression ISO Bortezomib results in decreased expression of AP2A1 mRNA CTD PMID:20977926 NCBI chr 1:100,896,582...100,926,443
Ensembl chr 1:100,896,947...100,926,335
JBrowse link
G Apobr apolipoprotein B receptor decreases expression ISO Bortezomib results in decreased expression of APOBR mRNA CTD PMID:20977926 NCBI chr 1:197,999,209...198,003,839
Ensembl chr 1:197,999,037...198,003,839
JBrowse link
G Apool apolipoprotein O-like increases expression ISO Bortezomib results in increased expression of APOOL mRNA CTD PMID:20977926 NCBI chr  X:83,678,269...83,750,550
Ensembl chr  X:83,678,339...83,750,549
JBrowse link
G Aqp3 aquaporin 3 (Gill blood group) increases expression ISO Bortezomib results in increased expression of AQP3 mRNA CTD PMID:20977926 NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
JBrowse link
G Ar androgen receptor multiple interactions ISO Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein] CTD PMID:25752796, PMID:30818834 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Arf6 ADP-ribosylation factor 6 increases expression ISO Bortezomib results in increased expression of ARF6 mRNA CTD PMID:20977926 NCBI chr 6:91,697,109...91,698,257
Ensembl chr 6:91,697,109...91,698,255
JBrowse link
G Arfgap1 ADP-ribosylation factor GTPase activating protein 1 decreases expression ISO Bortezomib results in decreased expression of ARFGAP1 mRNA CTD PMID:20977926 NCBI chr 3:176,475,847...176,490,642
Ensembl chr 3:176,475,893...176,489,925
JBrowse link
G Arhgap1 Rho GTPase activating protein 1 decreases expression ISO Bortezomib results in decreased expression of ARHGAP1 mRNA CTD PMID:20977926 NCBI chr 3:80,555,196...80,576,881
Ensembl chr 3:80,555,196...80,576,856
JBrowse link
G Arhgdia Rho GDP dissociation inhibitor alpha decreases expression ISO Bortezomib results in decreased expression of ARHGDIA mRNA CTD PMID:20977926 NCBI chr10:109,754,012...109,757,506
Ensembl chr10:109,754,004...109,757,550
JBrowse link
G Arid3b AT-rich interaction domain 3B multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA CTD PMID:25522274 NCBI chr 8:62,569,601...62,616,837
Ensembl chr 8:62,569,528...62,616,828
JBrowse link
G Arl4c ADP ribosylation factor like GTPase 4C decreases expression ISO Bortezomib results in decreased expression of ARL4C mRNA CTD PMID:20977926 NCBI chr 9:95,783,651...95,787,092
Ensembl chr 9:95,786,508...95,787,094
JBrowse link
G Arl8a ADP-ribosylation factor like GTPase 8A increases expression ISO Bortezomib results in increased expression of ARL8A mRNA CTD PMID:20977926 NCBI chr13:51,972,974...51,981,976
Ensembl chr13:51,972,974...51,981,976
JBrowse link
G Arrb1 arrestin, beta 1 decreases expression ISO Bortezomib results in decreased expression of ARRB1 mRNA CTD PMID:20977926 NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
JBrowse link
G Asap1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 decreases expression ISO Bortezomib results in decreased expression of ASAP1 mRNA CTD PMID:20977926 NCBI chr 7:104,670,076...104,951,090
Ensembl chr 7:104,669,672...104,801,045
JBrowse link
G Ate1 arginyltransferase 1 increases expression ISO Bortezomib results in increased expression of ATE1 mRNA CTD PMID:20977926 NCBI chr 1:200,810,741...200,885,593
NCBI chr 1:200,958,564...201,082,100
Ensembl chr 1:200,810,771...201,082,727
JBrowse link
G Atf2 activating transcription factor 2 multiple interactions
increases phosphorylation
increases expression
ISO pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein]
Bortezomib results in increased expression of ATF2 mRNA
CTD PMID:12393500, PMID:20977926 NCBI chr 3:60,721,137...60,795,951
Ensembl chr 3:60,721,135...60,795,951
JBrowse link
G Atf3 activating transcription factor 3 increases response to substance
increases expression
multiple interactions
ISO
EXP
ATF3 results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]
CTD PMID:17898295, PMID:20022965, PMID:20830808, PMID:21762082, PMID:25522274 NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression
decreases response to substance
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA]
Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein
ATF4 results in decreased susceptibility to Bortezomib
CTD PMID:15509775, PMID:16928686, PMID:20022965 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atf5 activating transcription factor 5 increases expression ISO Bortezomib results in increased expression of ATF5 mRNA CTD PMID:17898295 NCBI chr 1:100,807,821...100,812,410
Ensembl chr 1:100,808,241...100,810,522
JBrowse link
G Atg5 autophagy related 5 multiple interactions ISO ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]] CTD PMID:22842577 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Atm ATM serine/threonine kinase multiple interactions
increases cleavage
ISO [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein] CTD PMID:12393500 NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
JBrowse link
G Atp1a3 ATPase Na+/K+ transporting subunit alpha 3 decreases expression ISO Bortezomib results in decreased expression of ATP1A3 mRNA CTD PMID:20977926 NCBI chr 1:81,852,423...81,881,565
Ensembl chr 1:81,852,429...81,881,549
JBrowse link
G Atp2a1 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 multiple interactions
affects response to substance
ISO ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]
ATP2A1 protein affects the susceptibility to Bortezomib
CTD PMID:25576094 NCBI chr 1:197,855,912...197,875,038 JBrowse link
G Atp6v0e1 ATPase H+ transporting V0 subunit e1 increases expression ISO Bortezomib results in increased expression of ATP6V0E1 mRNA CTD PMID:20977926 NCBI chr10:16,769,857...16,792,930
Ensembl chr10:16,769,666...16,792,909
JBrowse link
G B2m beta-2 microglobulin decreases expression ISO Bortezomib results in decreased expression of B2M protein CTD PMID:17204182 NCBI chr 3:114,087,287...114,093,311
Ensembl chr 3:114,087,287...114,093,309
JBrowse link
G B3gnt2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 decreases expression ISO Bortezomib results in decreased expression of B3GNT2 mRNA CTD PMID:20977926 NCBI chr14:107,592,336...107,617,189
Ensembl chr14:107,592,336...107,617,161
JBrowse link
G B4galt6 beta-1,4-galactosyltransferase 6 increases expression ISO Bortezomib results in increased expression of B4GALT6 mRNA CTD PMID:20977926 NCBI chr18:15,462,913...15,525,584
Ensembl chr18:15,462,913...15,525,579
JBrowse link
G Bag3 BAG cochaperone 3 increases expression ISO Bortezomib results in increased expression of BAG3 mRNA CTD PMID:15509775, PMID:17659339, PMID:20471514 NCBI chr 1:199,941,258...199,965,191
Ensembl chr 1:199,941,161...199,965,191
JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions
increases expression
ISO [nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]
BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein]
Bortezomib results in increased expression of BAK1 protein
CTD PMID:12902978, PMID:17326159, PMID:20850924 NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
JBrowse link
G Bard1 BRCA1 associated RING domain 1 increases response to substance ISO BARD1 mutant form results in increased susceptibility to Bortezomib CTD PMID:25522274 NCBI chr 9:78,297,723...78,368,777
Ensembl chr 9:78,294,834...78,369,031
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
ISO [Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]
Bortezomib results in increased expression of BAX protein
CTD PMID:12902978, PMID:18445700, PMID:18718063, PMID:20383943, PMID:20850924 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bbc3 Bcl-2 binding component 3 increases expression ISO Bortezomib results in increased expression of BBC3 mRNA; Bortezomib results in increased expression of BBC3 protein CTD PMID:17898295, PMID:20051518 NCBI chr 1:78,261,491...78,267,802 JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
increases expression
increases cleavage
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form]
Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein
Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein
CTD PMID:15173093, PMID:15781649, PMID:16022909, PMID:16118318, PMID:16446371, PMID:17156654, PMID:17326159, PMID:17327374, PMID:17351739, PMID:17895889, PMID:18718063, PMID:18928586, PMID:20051518, PMID:20383943, PMID:20471514, PMID:21302442, PMID:24377552 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2a1 BCL2-related protein A1 multiple interactions
increases expression
ISO [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein
Bortezomib results in increased expression of BCL2A1A protein
CTD PMID:18223231, PMID:20051518 NCBI chr 8:96,551,424...96,559,527
Ensembl chr 8:96,551,245...96,559,483
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases expression
increases expression
increases cleavage
decreases response to substance
ISO [alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]
Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein
Bortezomib results in increased expression of BCL2L1 protein
BCL2L1 protein results in decreased susceptibility to Bortezomib
CTD PMID:15039284, PMID:15543232, PMID:15781649, PMID:16118318, PMID:16446371, PMID:16617327, PMID:16904634, PMID:17326159, PMID:17327374, PMID:17351739, PMID:18223231, PMID:19100720, PMID:20051518 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
increases activity
increases response to substance
ISO [Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein]
Bortezomib results in increased expression of BCL2L11 protein
Bortezomib results in increased activity of BCL2L11 protein
BCL2L11 results in increased susceptibility to Bortezomib
CTD PMID:15173094, PMID:16024631, PMID:16446371, PMID:17326159, PMID:18566236 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Bcl2l2 Bcl2-like 2 increases expression ISO Bortezomib results in increased expression of BCL2L2 mRNA CTD PMID:18928586 NCBI chr15:33,543,774...33,549,165
Ensembl chr15:33,544,312...33,549,164
JBrowse link
G Bcl3 BCL3, transcription coactivator multiple interactions
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL3 mRNA
Bortezomib results in decreased expression of BCL3 mRNA
CTD PMID:20471514, PMID:20977926 NCBI chr 1:80,730,758...80,745,273
Ensembl chr 1:80,730,499...80,744,831
JBrowse link
G Bcl6 BCL6, transcription repressor increases expression ISO Bortezomib results in increased expression of BCL6 mRNA CTD PMID:20977926 NCBI chr11:80,255,790...80,279,075
Ensembl chr11:80,255,790...80,279,075
JBrowse link
G Bcl7a BAF chromatin remodeling complex subunit BCL7A decreases expression ISO Bortezomib results in decreased expression of BCL7A mRNA CTD PMID:20977926 NCBI chr12:38,659,294...38,691,191
Ensembl chr12:38,662,303...38,691,075
JBrowse link
G Bcr BCR activator of RhoGEF and GTPase decreases expression ISO Bortezomib results in decreased expression of BCR mRNA CTD PMID:20977926 NCBI chr20:14,421,250...14,546,406
Ensembl chr20:14,421,141...14,545,772
JBrowse link
G Becn1 beclin 1 multiple interactions
decreases response to substance
ISO BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]
BECN1 protein results in decreased susceptibility to Bortezomib
CTD PMID:22842577 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Bid BH3 interacting domain death agonist increases cleavage
multiple interactions
ISO Bortezomib results in increased cleavage of BID protein
[Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]
CTD PMID:12893773, PMID:12902978, PMID:15930312, PMID:17326159, PMID:17351739, PMID:17898295, PMID:19261616 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Bik BCL2-interacting killer increases response to substance
increases expression
increases activity
ISO BIK results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of BIK protein
Bortezomib results in increased activity of BIK protein
CTD PMID:16446371, PMID:18566236 NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
JBrowse link
G Bin1 bridging integrator 1 increases expression ISO Bortezomib results in increased expression of BIN1 mRNA CTD PMID:17659339 NCBI chr18:25,163,575...25,222,139
Ensembl chr18:25,163,561...25,222,135
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of BIRC2 protein
[geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein
CTD PMID:15543232, PMID:15781649, PMID:17626072, PMID:18223231 NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression
increases expression
multiple interactions
ISO Bortezomib results in decreased expression of BIRC3 protein
Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA
CTD PMID:17626072, PMID:24085292, PMID:25522274 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions
increases expression
ISO Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein
[irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein
Bortezomib results in increased expression of BIRC5 protein
CTD PMID:16373703, PMID:17510429, PMID:17898295, PMID:18223231, PMID:18850583, PMID:19636294, PMID:20977926 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Birc7 baculoviral IAP repeat-containing 7 multiple interactions
decreases expression
ISO arsenic trioxide promotes the reaction [Bortezomib results in decreased expression of BIRC7 mRNA] CTD PMID:21867610 NCBI chr 3:176,438,335...176,443,864
Ensembl chr 3:176,439,199...176,443,195
JBrowse link
G Bles03 basophilic leukemia expressed protein BLES03 decreases expression ISO Bortezomib results in decreased expression of C11ORF68 mRNA CTD PMID:20977926 NCBI chr 1:220,806,563...220,808,817
Ensembl chr 1:220,806,473...220,808,804
JBrowse link
G Blk BLK proto-oncogene, Src family tyrosine kinase decreases expression ISO Bortezomib results in decreased expression of BLK mRNA CTD PMID:20977926 NCBI chr15:46,555,552...46,593,778
Ensembl chr15:46,555,188...46,593,653
JBrowse link
G Blvrb biliverdin reductase B increases expression ISO Bortezomib results in increased expression of BLVRB mRNA CTD PMID:20977926 NCBI chr 1:84,256,063...84,273,726
Ensembl chr 1:84,256,159...84,274,075
JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression ISO Bortezomib results in increased expression of BNIP3 protein CTD PMID:20110775 NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
JBrowse link
G Brca1 BRCA1, DNA repair associated decreases expression
multiple interactions
increases response to substance
decreases ubiquitination
ISO Bortezomib results in decreased expression of BRCA1 mRNA
BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib]
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein]
Bortezomib results in decreased ubiquitination of BRCA1 protein
CTD PMID:21917757, PMID:25522274 NCBI chr10:89,394,821...89,455,093
Ensembl chr10:89,394,803...89,454,681
JBrowse link
G Brca2 BRCA2, DNA repair associated decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of BRCA2 mRNA
[arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA
CTD PMID:21917757, PMID:25913414 NCBI chr12:503,660...544,754
Ensembl chr12:504,007...544,748
JBrowse link
G Brcc3 BRCA1/BRCA2-containing complex, subunit 3 decreases expression ISO Bortezomib results in decreased expression of BRCC3 mRNA CTD PMID:20977926 NCBI chr 9:9,863,380...9,865,920
Ensembl chr 9:9,863,404...9,865,920
JBrowse link
G Brf2 BRF2, RNA polymerase III transcription initiation factor subunit increases expression ISO Bortezomib results in increased expression of BRF2 mRNA CTD PMID:20977926 NCBI chr16:69,089,955...69,094,678
Ensembl chr16:69,089,955...69,094,680
JBrowse link
G Bsdc1 BSD domain containing 1 increases expression ISO Bortezomib results in increased expression of BSDC1 mRNA CTD PMID:20977926 NCBI chr 5:147,661,618...147,689,766
Ensembl chr 5:147,661,618...147,689,759
JBrowse link
G Ca9 carbonic anhydrase 9 decreases expression ISO Bortezomib results in decreased expression of CA9 protein CTD PMID:16061869 NCBI chr 5:59,008,277...59,015,535
Ensembl chr 5:59,008,933...59,015,528
JBrowse link
G Caap1 caspase activity and apoptosis inhibitor 1 increases expression ISO Bortezomib results in increased expression of CAAP1 mRNA CTD PMID:20977926 NCBI chr 5:113,479,416...113,532,961
Ensembl chr 5:113,480,547...113,532,878
JBrowse link
G Cacna1h calcium voltage-gated channel subunit alpha1 H decreases degradation ISO Bortezomib results in decreased degradation of CACNA1H protein CTD PMID:30552955 NCBI chr10:14,730,932...14,789,201
Ensembl chr10:14,730,941...14,788,617
JBrowse link
G Calr calreticulin multiple interactions
increases expression
ISO [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein]
[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]
CTD PMID:30482226 NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
JBrowse link
G Capn15 calpain 15 decreases expression ISO Bortezomib results in decreased expression of CAPN15 mRNA CTD PMID:20977926 NCBI chr10:15,319,772...15,346,607
Ensembl chr10:15,319,774...15,346,374
JBrowse link
G Card9 caspase recruitment domain family, member 9 multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of CARD9 mRNA CTD PMID:20471514 NCBI chr 3:3,798,346...3,806,841
Ensembl chr 3:3,798,347...3,806,713
JBrowse link
G Casp12 caspase 12 increases cleavage ISO Bortezomib results in increased cleavage of CASP12 protein CTD PMID:15509775, PMID:16357177 NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
JBrowse link
G Casp2 caspase 2 multiple interactions
increases response to substance
increases cleavage
ISO benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]
CASP2 results in increased susceptibility to Bortezomib
Bortezomib results in increased cleavage of CASP2 protein
CTD PMID:15509775, PMID:16446371, PMID:18723477 NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
JBrowse link
G Casp3 caspase 3 increases activity
increases cleavage
multiple interactions
increases expression
ISO Bortezomib results in increased activity of CASP3 protein
Bortezomib results in increased cleavage of CASP3 protein
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [SCIO-469 co-treated with Bortezomib] results in increased activity of CASP3 protein; ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased activity of CASP3 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP3 protein; [Bortezomib co-treated with abexinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP3 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [Cisplatin co-treated with Bortezomib] results in increased activity of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased activity of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [gallium nitrate results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [NSC606985 results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Thapsigargin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Tunicamycin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]
Bortezomib results in increased expression of CASP3 protein
CTD PMID:12393500, PMID:12893773, PMID:15070698, PMID:15173093, PMID:15509775, PMID:15514602, PMID:15930312, PMID:16024631, PMID:16118318, PMID:16357177, PMID:16617327, PMID:16675587, PMID:16778179, PMID:16904634, PMID:16985072, PMID:17121930, PMID:17156654, PMID:17326159, PMID:17351739, PMID:17495969, PMID:17510429, PMID:17898295, PMID:17898787, PMID:18005386, PMID:18223231, PMID:18223318, PMID:18342500, PMID:18534018, PMID:18641367, PMID:18718063, PMID:18790767, PMID:19100720, PMID:19261616, PMID:19417023, PMID:19662097, PMID:20022965, PMID:20051518, PMID:20150630, PMID:20383943, PMID:20471514, PMID:20524303, PMID:20850924, PMID:21195056, PMID:21345073, PMID:21472287, PMID:21518486, PMID:22842577, PMID:23063726, PMID:23300809, PMID:24291039, PMID:24377552, PMID:29384525, PMID:30482226 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp4 caspase 4 multiple interactions
increases response to substance
increases cleavage
increases activity
ISO [Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein; CASP4 protein results in increased susceptibility to [Cisplatin co-treated with Bortezomib]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein]
CASP4 protein results in increased susceptibility to Bortezomib
Bortezomib results in increased activity of CASP4 protein
CTD PMID:16357177, PMID:18641367 NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
JBrowse link
G Casp6 caspase 6 multiple interactions
increases cleavage
ISO Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP6 protein] CTD PMID:16617327, PMID:17510429 NCBI chr 2:235,341,326...235,353,715
Ensembl chr 2:235,341,365...235,353,967
Ensembl chr 2:235,341,365...235,353,967
JBrowse link
G Casp7 caspase 7 multiple interactions
increases cleavage
increases activity
ISO [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein; Bortezomib results in increased cleavage of and results in increased activity of CASP7 protein; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP7 protein]
Bortezomib results in increased activity of CASP7 protein
CTD PMID:16024631, PMID:16617327, PMID:16904634, PMID:18342500, PMID:18534018, PMID:20022965, PMID:20524303, PMID:23300809 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp8 caspase 8 multiple interactions
increases cleavage
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of CASP8 mRNA; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP8 protein; [Bortezomib co-treated with arsenic trioxide] results in increased expression of CASP8 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with vorinostat] results in increased activity of CASP8 protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [IFNA2 protein co-treated with Bortezomib] results in increased activity of CASP8 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of CASP8 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [vorinostat results in increased activity of CASP8 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP8 protein; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP8 protein] CTD PMID:12393500, PMID:12893773, PMID:12902978, PMID:15070698, PMID:15173093, PMID:15930312, PMID:16024631, PMID:16118318, PMID:16617327, PMID:16778179, PMID:16904634, PMID:17172406, PMID:17326159, PMID:17351739, PMID:17510429, PMID:17620439, PMID:17626072, PMID:17659339, PMID:17898787, PMID:18005386, PMID:18641367, PMID:19100720, PMID:19261616, PMID:19417023, PMID:20051518, PMID:20442297, PMID:20471514, PMID:21345073, PMID:24291039, PMID:24377552 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions
increases expression
increases response to substance
increases cleavage
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP9 protein; [Bortezomib co-treated with arsenic trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with arsenic trioxide] results in increased expression of CASP9 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with vorinostat] results in increased activity of CASP9 protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [vorinostat results in increased activity of CASP9 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]
Bortezomib results in increased expression of CASP9 protein
CASP9 gene SNP results in increased susceptibility to Bortezomib; CASP9 results in increased susceptibility to Bortezomib
CTD PMID:12893773, PMID:15070698, PMID:15173093, PMID:15509775, PMID:16024631, PMID:16118318, PMID:16617327, PMID:16778179, PMID:16904634, PMID:16985072, PMID:17156654, PMID:17326159, PMID:17510429, PMID:17620439, PMID:17626072, PMID:17898295, PMID:17898787, PMID:18005386, PMID:18223231, PMID:18641367, PMID:18723477, PMID:19261616, PMID:19417023, PMID:20051518, PMID:20471514, PMID:20850924, PMID:20864405, PMID:21345073, PMID:21518486, PMID:24291039, PMID:24377552 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cbl Cbl proto-oncogene multiple interactions ISO [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein] CTD PMID:19457607 NCBI chr 8:48,481,256...48,564,775
Ensembl chr 8:48,489,036...48,564,722
JBrowse link
G Cbr3 carbonyl reductase 3 increases expression ISO [Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of CBR3 mRNA CTD PMID:20806931, PMID:20977926 NCBI chr11:33,909,417...33,917,674
Ensembl chr11:33,909,439...33,917,674
JBrowse link
G Cbx3 chromobox 3 increases expression ISO Bortezomib results in increased expression of CBX3 mRNA CTD PMID:20977926 NCBI chr 4:81,243,809...81,257,898
Ensembl chr 4:81,244,469...81,257,897
JBrowse link
G Ccar1 cell division cycle and apoptosis regulator 1 increases expression ISO Bortezomib results in increased expression of CCAR1 protein CTD PMID:21594647, PMID:21903591 NCBI chr20:32,373,443...32,416,044
Ensembl chr20:32,373,443...32,416,044
JBrowse link
G Ccdc186 coiled-coil domain containing 186 increases expression ISO Bortezomib results in increased expression of CCDC186 mRNA CTD PMID:20977926 NCBI chr 1:277,603,601...277,635,379
Ensembl chr 1:277,606,995...277,629,196
JBrowse link
G Ccdc32 coiled-coil domain containing 32 increases expression ISO Bortezomib results in increased expression of CCDC32 mRNA CTD PMID:20977926 NCBI chr 3:110,816,327...110,828,824
Ensembl chr 3:110,816,337...110,828,879
JBrowse link
G Ccdc6 coiled-coil domain containing 6 decreases expression ISO Bortezomib results in decreased expression of CCDC6 mRNA CTD PMID:20977926 NCBI chr20:19,729,005...19,825,219
Ensembl chr20:19,732,894...19,825,150
JBrowse link
G Ccdc82 coiled-coil domain containing 82 increases expression ISO Bortezomib results in increased expression of CCDC82 mRNA CTD PMID:20977926 NCBI chr 8:11,888,460...11,927,920
Ensembl chr 8:11,888,591...11,927,919
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression ISO Bortezomib results in decreased expression of CCL2 mRNA CTD PMID:20471514 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases expression
decreases expression
EXP
ISO
Bortezomib results in increased expression of CCL3 mRNA; Bortezomib results in increased expression of CCL3 protein
Bortezomib results in decreased expression of CCL3 mRNA
CTD PMID:18089816, PMID:20830808 NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
JBrowse link
G Ccnb1 cyclin B1 multiple interactions
increases expression
ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; Bortezomib results in increased ubiquitination of and results in increased expression of CCNB1 protein
Bortezomib results in increased expression of CCNB1 protein
CTD PMID:19074855, PMID:20367638, PMID:25522274 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of CCND1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of CCND1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of CCND1 protein] CTD PMID:12893773, PMID:15173093, PMID:15781649 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO Bortezomib results in decreased expression of CCND2 mRNA CTD PMID:20977926 NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
JBrowse link
G Ccnf cyclin F multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA CTD PMID:25522274 NCBI chr10:13,594,687...13,619,935
Ensembl chr10:13,594,687...13,619,935
JBrowse link
G Ccng2 cyclin G2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA CTD PMID:25522274 NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068
JBrowse link
G Ccpg1 cell cycle progression 1 increases expression ISO Bortezomib results in increased expression of CCPG1 mRNA CTD PMID:20471514, PMID:20977926 NCBI chr 8:79,660,634...79,692,044
Ensembl chr 8:79,660,657...79,692,039
JBrowse link
G Cd27 CD27 molecule increases expression ISO Bortezomib results in increased expression of CD27 mRNA CTD PMID:17895889 NCBI chr 4:157,744,881...157,751,609
Ensembl chr 4:157,744,882...157,750,088
JBrowse link
G Cd38 CD38 molecule decreases expression ISO Bortezomib results in decreased expression of CD38 mRNA CTD PMID:20977926 NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
JBrowse link
G Cd5 Cd5 molecule decreases expression ISO Bortezomib results in decreased expression of CD5 mRNA CTD PMID:20977926 NCBI chr 1:226,770,912...226,791,861
Ensembl chr 1:226,770,744...226,791,879
JBrowse link
G Cd69 Cd69 molecule increases expression ISO Bortezomib results in increased expression of CD69 mRNA CTD PMID:20977926 NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084
JBrowse link
G Cd79a CD79a molecule decreases expression ISO Bortezomib results in decreased expression of CD79A mRNA CTD PMID:20977926 NCBI chr 1:81,763,609...81,768,039
Ensembl chr 1:81,763,614...81,767,980
JBrowse link
G Cd82 Cd82 molecule decreases expression ISO Bortezomib results in decreased expression of CD82 mRNA CTD PMID:20977926 NCBI chr 3:82,324,344...82,368,846
Ensembl chr 3:82,324,354...82,368,357
JBrowse link
G Cd9 CD9 molecule increases expression ISO Bortezomib results in increased expression of CD9 mRNA CTD PMID:20977926 NCBI chr 4:157,977,163...158,010,091
Ensembl chr 4:157,977,162...158,010,166
JBrowse link
G Cdc23 cell division cycle 23 increases expression ISO Bortezomib results in increased expression of CDC23 mRNA CTD PMID:20977926 NCBI chr18:27,430,924...27,452,569
Ensembl chr18:27,430,905...27,452,420
JBrowse link
G Cdc34 cell division cycle 34, ubiqiutin conjugating enzyme increases expression ISO Bortezomib results in increased expression of CDC34 mRNA CTD PMID:20977926 NCBI chr 7:12,899,957...12,905,339
Ensembl chr 7:12,899,958...12,905,339
JBrowse link
G Cdc37 cell division cycle 37, HSP90 cochaperone increases expression ISO Bortezomib results in increased expression of CDC37 mRNA CTD PMID:17895889 NCBI chr 8:22,160,922...22,173,797
Ensembl chr 8:22,154,067...22,173,804
JBrowse link
G Cdc42 cell division cycle 42 decreases expression ISO Bortezomib results in decreased expression of CDC42 mRNA CTD PMID:20977926 NCBI chr 5:155,690,267...155,728,385
Ensembl chr 5:155,691,390...155,728,300
JBrowse link
G Cdc42se2 CDC42 small effector 2 decreases expression ISO Bortezomib results in decreased expression of CDC42SE2 mRNA CTD PMID:20977926 NCBI chr10:40,054,393...40,122,915
Ensembl chr10:40,054,400...40,122,915
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions
increases phosphorylation
increases activity
decreases activity
ISO Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK1 protein]
Bortezomib results in increased phosphorylation of CDK1 protein
Bortezomib results in increased activity of CDK1 protein
Bortezomib results in decreased activity of CDK1 protein
CTD PMID:14749476, PMID:16928825, PMID:19074855, PMID:20367638 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions
decreases activity
ISO Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK2 protein]
Bortezomib results in decreased activity of CDK2 protein
CTD PMID:14749476 NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases stability
multiple interactions
decreases response to substance
increases expression
ISO Bortezomib results in increased stability of CDKN1A protein
[Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with Butyrates] results in increased expression of and results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased expression of and results in increased cleavage of CDKN1A protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A mRNA; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1A protein; Bortezomib promotes the reaction [abexinostat results in increased expression of CDKN1A protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; CDKN1A results in decreased susceptibility to [Bortezomib co-treated with docetaxel]
CDKN1A results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of CDKN1A mRNA; Bortezomib results in increased expression of CDKN1A protein
CTD PMID:12893773, PMID:12902978, PMID:14749476, PMID:15173093, PMID:15543232, PMID:15930312, PMID:16928825, PMID:17327374, PMID:17898295, PMID:18223318, PMID:18445700, PMID:18790767, PMID:19220424, PMID:19417023, PMID:20383943, PMID:20977926, PMID:21345073 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases stability
increases expression
ISO [Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1B protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of CDKN1B protein; [Vorinostat co-treated with Bortezomib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Cisplatin promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]
Bortezomib results in increased stability of CDKN1B protein
CTD PMID:14749476, PMID:15173093, PMID:15543232, PMID:18223318, PMID:18445700, PMID:18850583, PMID:19220424, PMID:19636294, PMID:20701607 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cdt1 chromatin licensing and DNA replication factor 1 decreases expression ISO Bortezomib results in decreased expression of CDT1 mRNA CTD PMID:17659339 NCBI chr19:55,381,565...55,386,511
Ensembl chr19:55,381,565...55,386,511
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO Bortezomib inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein] CTD PMID:19662097 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions
increases expression
decreases expression
ISO
EXP
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Bortezomib inhibits the reaction [Arsenic Trioxide results in decreased expression of CEBPB mRNA]; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]
Bortezomib results in decreased expression of CEBPB mRNA
CTD PMID:20471514, PMID:20830808, PMID:30482226 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
JBrowse link
G Cenpc centromere protein C increases expression ISO Bortezomib results in increased expression of CENPC mRNA CTD PMID:20977926 NCBI chr14:23,611,909...23,670,314
Ensembl chr14:23,611,735...23,670,475
JBrowse link
G Cep290 centrosomal protein 290 increases expression ISO Bortezomib results in increased expression of CEP290 mRNA CTD PMID:20977926 NCBI chr 7:40,217,269...40,306,327
Ensembl chr 7:40,217,269...40,306,327
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression
multiple interactions
decreases response to substance
decreases expression
increases expression
ISO Bortezomib affects the expression of CFLAR protein
[Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [romidepsin co-treated with Bortezomib] results in decreased expression of CFLAR protein; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein]
CFLAR protein alternative form results in decreased susceptibility to Bortezomib; CFLAR results in decreased susceptibility to Bortezomib
Bortezomib results in decreased expression of CFLAR mRNA; Bortezomib results in decreased expression of CFLAR protein
Bortezomib results in increased expression of CFLAR protein; Bortezomib results in increased expression of CFLAR protein alternative form; Bortezomib results in increased expression of CFLAR protein modified form
CTD PMID:17326159, PMID:17327374, PMID:17351739, PMID:17510429, PMID:17659339, PMID:18223231, PMID:19100720, PMID:19922463, PMID:20515944, PMID:20876774 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Cgref1 cell growth regulator with EF hand domain 1 increases expression ISO Bortezomib results in increased expression of CGREF1 mRNA CTD PMID:17895889 NCBI chr 6:26,797,126...26,809,132
Ensembl chr 6:26,797,126...26,809,129
JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 increases expression ISO Bortezomib results in increased expression of CHAC1 mRNA CTD PMID:15509775 NCBI chr 3:111,160,205...111,163,425
Ensembl chr 3:111,160,205...111,163,425
JBrowse link
G Chaf1a chromatin assembly factor 1 subunit A decreases expression ISO Bortezomib results in decreased expression of CHAF1A mRNA CTD PMID:17659339 NCBI chr 9:11,000,869...11,027,631
Ensembl chr 9:11,001,129...11,027,506
JBrowse link
G Chd2 chromodomain helicase DNA binding protein 2 increases expression ISO Bortezomib results in increased expression of CHD2 mRNA CTD PMID:20977926 NCBI chr 1:134,757,934...134,873,053
Ensembl chr 1:134,757,934...134,871,167
JBrowse link
G Chfr checkpoint with forkhead and ring finger domains decreases expression ISO Bortezomib results in decreased expression of CHFR mRNA CTD PMID:20977926 NCBI chr12:52,562,594...52,596,162
Ensembl chr12:52,562,597...52,596,076
JBrowse link
G Chst11 carbohydrate sulfotransferase 11 decreases expression ISO Bortezomib results in decreased expression of CHST11 mRNA CTD PMID:20977926 NCBI chr 7:26,641,856...26,890,503
Ensembl chr 7:26,645,422...26,859,716
JBrowse link
G Chst2 carbohydrate sulfotransferase 2 decreases expression ISO Bortezomib results in decreased expression of CHST2 mRNA CTD PMID:20977926 NCBI chr 8:103,186,759...103,190,612
Ensembl chr 8:103,188,651...103,190,243
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases expression
increases activity
ISO Bortezomib results in increased expression of CHUK mRNA
Bortezomib results in increased activity of CHUK protein
CTD PMID:20471514, PMID:24085292 NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
JBrowse link
G Cideb cell death-inducing DFFA-like effector b decreases expression ISO Bortezomib results in decreased expression of CIDEB mRNA CTD PMID:17659339 NCBI chr15:34,439,844...34,444,244
Ensembl chr15:34,439,876...34,444,244
JBrowse link
G Cilk1 ciliogenesis associated kinase 1 increases expression ISO Bortezomib results in increased expression of CILK1 mRNA CTD PMID:20977926 NCBI chr 8:85,413,998...85,473,374
Ensembl chr 8:85,413,537...85,472,694
JBrowse link
G Clec7a C-type lectin domain containing 7A increases expression ISO Bortezomib results in increased expression of CLEC7A mRNA CTD PMID:20977926 NCBI chr 4:163,216,152...163,227,367
Ensembl chr 4:163,216,163...163,227,334
JBrowse link
G Clip4 CAP-GLY domain containing linker protein family, member 4 increases expression ISO Bortezomib results in increased expression of CLIP4 mRNA CTD PMID:20977926 NCBI chr 6:23,222,020...23,316,962
Ensembl chr 6:23,222,021...23,316,962
JBrowse link
G Cln6 CLN6, transmembrane ER protein decreases expression ISO Bortezomib results in decreased expression of CLN6 mRNA CTD PMID:20977926 NCBI chr 8:67,733,215...67,748,170
Ensembl chr 8:67,733,215...67,748,172
JBrowse link
G Clptm1 CLPTM1 regulator of GABA type A receptor forward trafficking decreases expression ISO Bortezomib results in decreased expression of CLPTM1 mRNA CTD PMID:20977926 NCBI chr 1:80,549,051...80,580,665
Ensembl chr 1:80,549,043...80,580,662
JBrowse link
G Clu clusterin increases expression ISO Bortezomib results in increased expression of CLU mRNA CTD PMID:20977926 NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
JBrowse link
G Cox8a cytochrome c oxidase subunit 8A decreases expression ISO Bortezomib results in decreased expression of COX8A mRNA CTD PMID:30818834 NCBI chr 1:222,466,575...222,468,896
Ensembl chr 1:222,466,575...222,468,896
JBrowse link
G Cpt1c carnitine palmitoyltransferase 1c increases response to substance ISO CPT1C gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 1:100,955,094...100,970,579
Ensembl chr 1:100,955,095...100,969,560
JBrowse link
G Crebbp CREB binding protein decreases expression ISO Bortezomib results in decreased expression of CREBBP mRNA CTD PMID:25913414 NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039
JBrowse link
G Crem cAMP responsive element modulator increases expression ISO Bortezomib results in increased expression of CREM mRNA CTD PMID:20977926 NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
JBrowse link
G Crip2 cysteine-rich protein 2 decreases expression ISO Bortezomib results in decreased expression of CRIP2 mRNA CTD PMID:20977926 NCBI chr 6:137,953,545...137,958,491
Ensembl chr 6:137,953,545...137,958,490
JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein CTD PMID:15039284 NCBI chr11:87,338,606...87,356,644
Ensembl chr11:87,778,312...87,815,043
JBrowse link
G Cryab crystallin, alpha B multiple interactions
increases expression
ISO
EXP
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA
Bortezomib results in increased expression of CRYAB mRNA
CTD PMID:20830808, PMID:25522274 NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545
JBrowse link
G Cst7 cystatin F increases expression ISO Bortezomib results in increased expression of CST7 mRNA CTD PMID:20977926 NCBI chr 3:146,363,913...146,373,365
Ensembl chr 3:146,365,092...146,373,365
JBrowse link
G Ctdspl2 CTD small phosphatase like 2 decreases expression ISO Bortezomib results in decreased expression of CTDSPL2 mRNA CTD PMID:20977926 NCBI chr 3:113,906,803...113,957,289
Ensembl chr 3:113,918,629...113,960,101
JBrowse link
G Cth cystathionine gamma-lyase multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA CTD PMID:25522274 NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions
decreases response to substance
increases expression
ISO 2-methoxyestradiol inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; arsenic trioxide inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein] CTD PMID:18485479, PMID:19100720 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Ctsb cathepsin B multiple interactions
increases localization
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased localization of CTSB protein] CTD PMID:16446371 NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
JBrowse link
G Ctsd cathepsin D increases expression ISO Bortezomib results in increased expression of CTSD mRNA CTD PMID:20977926 NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
JBrowse link
G Cul1 cullin 1 increases expression ISO Bortezomib results in increased expression of CUL1 mRNA CTD PMID:17895889 NCBI chr 4:77,211,814...77,283,369
Ensembl chr 4:77,211,692...77,280,250
JBrowse link
G Cul3 cullin 3 decreases expression ISO Bortezomib results in decreased expression of CUL3 mRNA CTD PMID:17659339 NCBI chr 9:86,044,485...86,129,066
Ensembl chr 9:86,044,485...86,129,329
JBrowse link
G Cwf19l1 CWF19 like cell cycle control factor 1 decreases expression ISO Bortezomib results in decreased expression of CWF19L1 mRNA CTD PMID:20977926 NCBI chr 1:263,887,014...263,910,251
Ensembl chr 1:263,887,015...263,910,251
JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 increases expression ISO Bortezomib results in increased expression of CXCL1 mRNA CTD PMID:15509775 NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions
ISO
EXP
Bortezomib results in increased expression of CXCL2 mRNA
Bortezomib results in increased expression of CXCL2 mRNA; Bortezomib results in increased expression of CXCL2 protein
Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL2 mRNA]
CTD PMID:20830808, PMID:27194111 NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions
increases expression
ISO Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL1 mRNA]
Bortezomib results in increased expression of CXCL1 mRNA
CTD PMID:15509775, PMID:27194111 NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 decreases expression ISO Bortezomib results in decreased expression of CXCR4 mRNA CTD PMID:20977926 NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
JBrowse link
G Cyb5r1 cytochrome b5 reductase 1 increases expression ISO Bortezomib results in increased expression of CYB5R1 mRNA CTD PMID:20977926 NCBI chr13:51,229,697...51,236,447
Ensembl chr13:51,229,890...51,236,463
JBrowse link
G Cyba cytochrome b-245 alpha chain decreases expression ISO Bortezomib results in decreased expression of CYBA mRNA CTD PMID:20977926 NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
JBrowse link
G Cycs cytochrome c, somatic multiple interactions
affects localization
ISO [Bortezomib co-treated with Butyrates] affects the localization of CYCS protein; [Bortezomib co-treated with vorinostat] affects the localization of CYCS protein
Bortezomib affects the localization of CYCS protein
CTD PMID:12893773, PMID:16024631 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 affects metabolic processing ISO CYP1A2 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 affects metabolic processing ISO CYP2C19 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects metabolic processing ISO CYP2D6 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
JBrowse link
G Cyp2u1 cytochrome P450, family 2, subfamily u, polypeptide 1 increases expression ISO Bortezomib results in increased expression of CYP2U1 mRNA CTD PMID:20977926 NCBI chr 2:236,414,131...236,431,650
Ensembl chr 2:236,414,135...236,431,683
JBrowse link
G Cytip cytohesin 1 interacting protein increases expression ISO Bortezomib results in increased expression of CYTIP mRNA CTD PMID:20977926 NCBI chr 3:44,150,494...44,225,723
Ensembl chr 3:44,150,992...44,177,689
JBrowse link
G Dap3 death associated protein 3 increases expression ISO Bortezomib results in increased expression of DAP3 mRNA CTD PMID:17659339 NCBI chr 2:188,225,607...188,255,324
Ensembl chr 2:188,225,613...188,252,725
JBrowse link
G Dapk2 death-associated protein kinase 2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA CTD PMID:25522274 NCBI chr 8:71,822,107...71,941,941
Ensembl chr 8:71,822,129...71,941,910
JBrowse link
G Dazap2 DAZ associated protein 2 decreases expression ISO Bortezomib results in decreased expression of DAZAP2 mRNA CTD PMID:20977926 NCBI chr 7:142,238,780...142,244,301
Ensembl chr 7:142,239,035...142,243,241
JBrowse link
G Dbn1 drebrin 1 increases expression ISO Bortezomib results in increased expression of DBN1 mRNA CTD PMID:20977926 NCBI chr17:9,679,511...9,693,878
Ensembl chr17:9,679,628...9,693,820
JBrowse link
G Dcaf11 DDB1 and CUL4 associated factor 11 decreases expression ISO Bortezomib results in decreased expression of DCAF11 mRNA CTD PMID:20977926 NCBI chr15:34,233,840...34,244,512
Ensembl chr15:34,234,193...34,244,504
JBrowse link
G Dcaf13 DDB1 and CUL4 associated factor 13 increases expression ISO Bortezomib results in increased expression of DCAF13 mRNA CTD PMID:20977926 NCBI chr 7:78,005,232...78,040,220
Ensembl chr 7:78,005,232...78,040,214
JBrowse link
G Dcps decapping enzyme, scavenger decreases expression ISO Bortezomib results in decreased expression of DCPS mRNA CTD PMID:20977926 NCBI chr 8:36,321,992...36,374,665
Ensembl chr 8:36,321,993...36,374,673
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
decreases response to substance
ISO
EXP
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of DDIT3 protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]
Bortezomib results in increased expression of DDIT3 mRNA; Bortezomib results in increased expression of DDIT3 protein
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; [Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Nitroprusside inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]
DDIT3 results in decreased susceptibility to Bortezomib
CTD PMID:15509775, PMID:16024631, PMID:16357177, PMID:17659339, PMID:17709599, PMID:17898295, PMID:18723477, PMID:20022965, PMID:20110775, PMID:20830808, PMID:22959925, PMID:24291039, PMID:30482226 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Ddx11 DEAD/H-box helicase 11 decreases expression ISO Bortezomib results in decreased expression of DDX11 mRNA CTD PMID:20977926 NCBI chr 9:114,113,642...114,133,908
Ensembl chr 9:114,111,580...114,132,492
JBrowse link
G Deaf1 DEAF1 transcription factor decreases expression ISO Bortezomib results in decreased expression of DEAF1 mRNA CTD PMID:20977926 NCBI chr 1:214,283,787...214,317,466
Ensembl chr 1:214,283,790...214,317,466
JBrowse link
G Dedd2 death effector domain containing 2 increases expression ISO Bortezomib results in increased expression of DEDD2 mRNA CTD PMID:17659339 NCBI chr 1:82,073,024...82,089,028
Ensembl chr 1:82,072,544...82,088,275
JBrowse link
G Def6 DEF6 guanine nucleotide exchange factor decreases expression ISO Bortezomib results in decreased expression of DEF6 mRNA CTD PMID:20977926 NCBI chr20:7,788,120...7,809,011
Ensembl chr20:7,788,084...7,809,560
JBrowse link
G Dennd4a DENN domain containing 4A increases expression ISO Bortezomib results in increased expression of DENND4A mRNA CTD PMID:20977926 NCBI chr 8:70,293,355...70,406,675
Ensembl chr 8:70,317,586...70,406,751
JBrowse link
G Dennd4b DENN domain containing 4B increases expression ISO Bortezomib results in increased expression of DENND4B mRNA CTD PMID:15509775 NCBI chr 2:189,626,922...189,642,732
Ensembl chr 2:189,629,297...189,642,183
JBrowse link
G Dennd4c DENN domain containing 4C increases expression ISO Bortezomib results in increased expression of DENND4C mRNA CTD PMID:20977926 NCBI chr 5:105,100,081...105,195,634
Ensembl chr 5:105,114,433...105,193,988
JBrowse link
G Dgke diacylglycerol kinase epsilon decreases expression ISO Bortezomib results in decreased expression of DGKE mRNA CTD PMID:20977926 NCBI chr10:76,375,981...76,408,224
Ensembl chr10:76,386,471...76,407,989
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein affects localization
increases localization
increases expression
multiple interactions
ISO Bortezomib affects the localization of DIABLO protein
Bortezomib results in increased localization of DIABLO protein
Bortezomib results in increased expression of DIABLO mRNA; Bortezomib results in increased expression of DIABLO protein
[alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in decreased localization of DIABLO protein; [Bortezomib co-treated with Butyrates] affects the localization of DIABLO protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib co-treated with vorinostat] affects the localization of DIABLO protein; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein]
CTD PMID:12893773, PMID:12902978, PMID:14555532, PMID:15039284, PMID:15070698, PMID:16024631, PMID:17327374, PMID:25913414 NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
JBrowse link
G Dlgap5 DLG associated protein 5 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA CTD PMID:25522274 NCBI chr15:24,167,484...24,199,417
Ensembl chr15:24,167,486...24,199,341
JBrowse link
G Dnaaf5 dynein, axonemal, assembly factor 5 decreases expression ISO Bortezomib results in decreased expression of DNAAF5 mRNA CTD PMID:20977926 NCBI chr12:17,545,468...17,584,466
Ensembl chr12:17,545,468...17,584,466
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 increases expression ISO Bortezomib results in increased expression of DNAJB1 mRNA CTD PMID:15509775 NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
JBrowse link
G Dnajc14 DnaJ heat shock protein family (Hsp40) member C14 decreases expression ISO Bortezomib results in decreased expression of DNAJC14 mRNA CTD PMID:20977926 NCBI chr 7:3,229,026...3,242,265
Ensembl chr 7:3,230,320...3,242,265
JBrowse link
G Dnajc4 DnaJ heat shock protein family (Hsp40) member C4 decreases expression ISO Bortezomib results in decreased expression of DNAJC4 mRNA CTD PMID:20977926 NCBI chr 1:222,242,889...222,247,115
Ensembl chr 1:222,242,858...222,246,768
JBrowse link
G Dnm2 dynamin 2 decreases expression ISO Bortezomib results in decreased expression of DNM2 mRNA CTD PMID:20977926 NCBI chr 8:22,458,869...22,540,649
Ensembl chr 8:22,458,899...22,540,524
JBrowse link
G Dpy19l4 dpy-19 like 4 increases expression ISO Bortezomib results in increased expression of DPY19L4 mRNA CTD PMID:20977926 NCBI chr 5:24,503,074...24,560,077
Ensembl chr 5:24,504,614...24,560,063
JBrowse link
G Dst dystonin increases expression ISO Bortezomib results in increased expression of DST mRNA CTD PMID:17659339 NCBI chr 9:37,902,336...38,296,961
Ensembl chr 9:37,902,303...38,196,273
JBrowse link
G Dusp15 dual specificity phosphatase 15 decreases expression ISO Bortezomib results in decreased expression of DUSP15 mRNA CTD PMID:20977926 NCBI chr 3:148,417,990...148,428,494
Ensembl chr 3:148,417,993...148,428,494
JBrowse link
G Dusp4 dual specificity phosphatase 4 decreases expression ISO Bortezomib results in decreased expression of DUSP4 mRNA CTD PMID:20977926 NCBI chr16:61,080,767...61,090,973
Ensembl chr16:61,078,175...61,091,169
JBrowse link
G Dusp5 dual specificity phosphatase 5 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA CTD PMID:25522274 NCBI chr 1:274,245,184...274,258,595
Ensembl chr 1:274,245,184...274,258,595
JBrowse link
G Dync1i1 dynein cytoplasmic 1 intermediate chain 1 increases expression ISO Bortezomib results in increased expression of DYNC1I1 mRNA CTD PMID:20977926 NCBI chr 4:30,807,755...31,121,097
Ensembl chr 4:30,807,879...31,121,090
JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein CTD PMID:25522274 NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
JBrowse link
G Ecpas Ecm29 proteasome adaptor and scaffold increases expression ISO Bortezomib results in increased expression of ECPAS mRNA CTD PMID:20977926 NCBI chr 5:75,928,510...76,040,771
Ensembl chr 5:75,931,293...76,039,760
JBrowse link
G Edaradd EDAR-associated death domain increases expression ISO Bortezomib results in increased expression of EDARADD mRNA CTD PMID:17895889 NCBI chr17:90,802,280...90,843,476
Ensembl chr17:90,802,393...90,843,485
JBrowse link
G Egln3 egl-9 family hypoxia-inducible factor 3 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA CTD PMID:25522274 NCBI chr 6:75,050,329...75,075,795
Ensembl chr 6:75,050,329...75,075,795
JBrowse link
G Egr1 early growth response 1 increases expression ISO Bortezomib results in increased expression of EGR1 mRNA CTD PMID:20471514 NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
JBrowse link
G Egr2 early growth response 2 decreases expression ISO
EXP
Bortezomib results in decreased expression of EGR2 mRNA
Bortezomib results in decreased expression of EGR2 mRNA; Bortezomib results in decreased expression of EGR2 protein
CTD PMID:20830808 NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
JBrowse link
G Ehmt2 euchromatic histone lysine methyltransferase 2 decreases expression ISO Bortezomib results in decreased expression of EHMT2 mRNA CTD PMID:20977926 NCBI chr20:4,576,033...4,592,980
Ensembl chr20:4,576,057...4,592,980
JBrowse link
G Eif1 eukaryotic translation initiation factor 1 increases expression ISO Bortezomib results in increased expression of EIF1 mRNA CTD PMID:20977926 NCBI chr10:88,227,455...88,229,546
Ensembl chr10:88,227,360...88,229,765
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A decreases phosphorylation ISO Bortezomib results in decreased phosphorylation of EIF2A protein CTD PMID:18641367 NCBI chr 2:148,722,343...148,755,781
Ensembl chr 2:148,722,231...148,755,520
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 increases phosphorylation
multiple interactions
decreases response to substance
ISO Bortezomib results in increased phosphorylation of EIF2AK3 protein
Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]]
EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein]
EIF2AK3 results in decreased susceptibility to Bortezomib
CTD PMID:15509775, PMID:16928686, PMID:20022965, PMID:22959925 NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions
increases phosphorylation
ISO Bortezomib inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein] CTD PMID:16357177, PMID:20022965, PMID:21090173 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
JBrowse link
G Eif2s3 eukaryotic translation initiation factor 2 subunit gamma decreases expression ISO Bortezomib results in decreased expression of EIF2S3 mRNA CTD PMID:20977926 NCBI chr  X:63,268,106...63,291,125
Ensembl chr  X:63,268,037...63,292,092
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions ISO [trichostatin A co-treated with Bortezomib] results in decreased phosphorylation of EIF4EBP1 protein CTD PMID:21345073 NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
JBrowse link
G Eif5a eukaryotic translation initiation factor 5A decreases expression ISO Bortezomib results in decreased expression of EIF5A mRNA CTD PMID:20977926 NCBI chr10:56,527,075...56,531,615
Ensembl chr10:56,527,085...56,531,483
JBrowse link
G Elp5 elongator acetyltransferase complex subunit 5 decreases expression ISO Bortezomib results in decreased expression of ELP5 mRNA CTD PMID:20977926 NCBI chr10:56,578,980...56,590,706
Ensembl chr10:56,578,985...56,591,364
JBrowse link
G Eno2 enolase 2 increases expression ISO Bortezomib results in increased expression of ENO2 mRNA CTD PMID:20977926 NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
JBrowse link
G Epha1 Eph receptor A1 decreases expression ISO Bortezomib results in decreased expression of EPHA1 mRNA CTD PMID:20977926 NCBI chr 4:71,749,100...71,763,681
Ensembl chr 4:71,749,242...71,763,679
JBrowse link
G Ephb2 Eph receptor B2 decreases expression ISO Bortezomib results in decreased expression of EPHB2 mRNA CTD PMID:20977926 NCBI chr 5:155,024,478...155,143,539
Ensembl chr 5:155,022,493...155,204,456
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases phosphorylation
ISO Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein]; lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein] CTD PMID:20701607 NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
JBrowse link
G Ercc3 ERCC excision repair 3, TFIIH core complex helicase subunit increases response to substance ISO ERCC3 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr18:25,037,668...25,068,380
Ensembl chr18:25,037,625...25,068,389
JBrowse link
G Ercc4 ERCC excision repair 4, endonuclease catalytic subunit increases response to substance ISO ERCC4 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr10:2,010,140...2,037,953
Ensembl chr10:2,010,648...2,037,891
JBrowse link
G Erlin2 ER lipid raft associated 2 decreases expression ISO Bortezomib results in decreased expression of ERLIN2 mRNA CTD PMID:20977926 NCBI chr16:69,179,005...69,195,452
Ensembl chr16:69,179,588...69,195,097
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions
decreases response to substance
ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA
ERN1 results in decreased susceptibility to Bortezomib
CTD PMID:16357177, PMID:25522274 NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
JBrowse link
G Esf1 ESF1 nucleolar pre-rRNA processing protein homolog increases expression ISO Bortezomib results in increased expression of ESF1 mRNA CTD PMID:20977926 NCBI chr 3:133,178,591...133,232,358
Ensembl chr 3:133,178,561...133,232,322
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO Bortezomib binds to and results in decreased activity of ESR1 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein] CTD PMID:25752796, PMID:30818834 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ESR2 mRNA; Bortezomib binds to and results in decreased activity of ESR2 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein] CTD PMID:25752796, PMID:25913414, PMID:30818834 NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
JBrowse link
G Esrra estrogen related receptor, alpha decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of ESRRA mRNA
Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; Bortezomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
CTD PMID:20977926, PMID:30818834 NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
JBrowse link
G Esyt2 extended synaptotagmin 2 decreases expression ISO Bortezomib results in decreased expression of ESYT2 mRNA CTD PMID:20977926 NCBI chr 6:144,156,021...144,248,374
Ensembl chr 6:144,156,175...144,245,545
JBrowse link
G Etv4 ETS variant transcription factor 4 decreases expression ISO Bortezomib results in decreased expression of ETV4 mRNA CTD PMID:20977926 NCBI chr10:89,685,058...89,700,300
Ensembl chr10:89,685,058...89,700,283
JBrowse link
G F2rl1 F2R like trypsin receptor 1 decreases expression ISO Bortezomib results in decreased expression of F2RL1 mRNA CTD PMID:20977926 NCBI chr 2:25,222,324...25,235,275
Ensembl chr 2:25,222,328...25,235,275
JBrowse link
G F3 coagulation factor III, tissue factor increases expression
multiple interactions
ISO Bortezomib results in increased expression of F3 protein
[Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein
CTD PMID:23696885 NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
JBrowse link
G Fads2 fatty acid desaturase 2 decreases expression ISO Bortezomib results in decreased expression of FADS2 mRNA CTD PMID:20977926 NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
JBrowse link
G Faf1 Fas associated factor 1 increases expression ISO Bortezomib results in increased expression of FAF1 mRNA CTD PMID:17895889 NCBI chr 5:129,370,767...129,738,393
Ensembl chr 5:129,448,879...129,738,252
JBrowse link
G Fam118b family with sequence similarity 118, member B increases expression ISO Bortezomib results in increased expression of FAM118B mRNA CTD PMID:20977926 NCBI chr 8:36,416,769...36,467,609
Ensembl chr 8:36,416,997...36,467,627
JBrowse link
G Fam168a family with sequence similarity 168, member A increases expression ISO Bortezomib results in increased expression of FAM168A mRNA CTD PMID:20977926 NCBI chr 1:165,723,278...165,880,612
Ensembl chr 1:165,724,451...165,878,652
JBrowse link
G Fam20b FAM20B, glycosaminoglycan xylosylkinase decreases expression ISO Bortezomib results in decreased expression of FAM20B mRNA CTD PMID:20977926 NCBI chr13:74,280,173...74,333,463
Ensembl chr13:74,280,173...74,331,214
JBrowse link
G Fam219a family with sequence similarity 219, member A increases expression ISO Bortezomib results in increased expression of FAM219A mRNA CTD PMID:20977926 NCBI chr 5:57,896,824...57,947,569
Ensembl chr 5:57,897,368...57,947,183
JBrowse link
G Fam241b family with sequence similarity 241 member B increases expression ISO Bortezomib results in increased expression of FAM241B mRNA CTD PMID:20977926 NCBI chr20:31,734,297...31,736,115
Ensembl chr20:31,734,183...31,736,212
JBrowse link
G Fam43a family with sequence similarity 43, member A decreases expression ISO Bortezomib results in decreased expression of FAM43A mRNA CTD PMID:20977926 NCBI chr11:73,676,601...73,679,003
Ensembl chr11:73,676,601...73,678,984
JBrowse link
G Fam76a family with sequence similarity 76, member A increases expression ISO Bortezomib results in increased expression of FAM76A mRNA CTD PMID:20977926 NCBI chr 5:151,087,962...151,117,142
Ensembl chr 5:151,089,900...151,117,042
JBrowse link
G Fancd2 FA complementation group D2 decreases expression ISO Bortezomib results in decreased expression of FANCD2 mRNA; Bortezomib results in decreased expression of FANCD2 protein CTD PMID:19934314, PMID:21917757 NCBI chr 4:145,489,869...145,551,479
Ensembl chr 4:145,489,869...145,551,479
JBrowse link
G Farsa phenylalanyl-tRNA synthetase subunit alpha decreases expression ISO Bortezomib results in decreased expression of FARSA mRNA CTD PMID:20977926 NCBI chr19:25,969,255...25,978,777
Ensembl chr19:25,969,255...25,978,776
JBrowse link
G Fas Fas cell surface death receptor multiple interactions
decreases expression
increases expression
ISO [Bortezomib co-treated with vorinostat] results in increased expression of FAS protein
Bortezomib results in decreased expression of FAS mRNA
Bortezomib results in increased expression of FAS mRNA; Bortezomib results in increased expression of FAS protein
CTD PMID:17351739, PMID:20471514, PMID:25913414 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
JBrowse link
G Faslg Fas ligand multiple interactions
increases expression
ISO [Bortezomib co-treated with vorinostat] results in increased expression of FASLG mRNA; [Bortezomib co-treated with vorinostat] results in increased expression of FASLG protein; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of FASLG]; Curcumin inhibits the reaction [[vorinostat co-treated with Bortezomib] results in increased expression of FASLG protein]
Bortezomib results in increased expression of FASLG protein
CTD PMID:17351739, PMID:20471514 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Fastk Fas-activated serine/threonine kinase decreases expression ISO Bortezomib results in decreased expression of FASTK mRNA CTD PMID:20977926 NCBI chr 4:7,260,521...7,264,590
Ensembl chr 4:7,260,575...7,264,589
JBrowse link
G Fbln5 fibulin 5 decreases expression ISO Bortezomib results in decreased expression of FBLN5 mRNA CTD PMID:20977926 NCBI chr 6:125,644,797...125,723,957
Ensembl chr 6:125,644,804...125,723,944
JBrowse link
G Fbxw7 F-box and WD repeat domain containing 7 decreases expression ISO Bortezomib results in decreased expression of FBXW7 mRNA CTD PMID:20977926 NCBI chr 2:184,230,191...184,309,805
Ensembl chr 2:184,231,260...184,309,664
JBrowse link
G Fgf21 fibroblast growth factor 21 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA CTD PMID:25522274 NCBI chr 1:101,595,579...101,596,822
Ensembl chr 1:101,595,579...101,596,822
JBrowse link
G Fgfr1op2 FGFR1 oncogene partner 2 increases expression ISO Bortezomib results in increased expression of FGFR1OP2 mRNA CTD PMID:20977926 NCBI chr 4:180,887,182...180,908,206
Ensembl chr 4:180,887,182...180,908,198
JBrowse link
G Fkbp1a FKBP prolyl isomerase 1A decreases expression ISO Bortezomib results in decreased expression of FKBP1A mRNA CTD PMID:20977926 NCBI chr 3:147,042,944...147,062,725
Ensembl chr 3:147,042,944...147,062,724
JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 decreases expression ISO Bortezomib results in decreased expression of FKBP5 mRNA CTD PMID:20977926 NCBI chr20:7,976,704...8,097,290
Ensembl chr20:7,976,713...8,019,020
JBrowse link
G Flcn folliculin increases expression ISO Bortezomib results in increased expression of FLCN mRNA CTD PMID:20977926 NCBI chr10:46,153,185...46,172,331
Ensembl chr10:46,153,188...46,172,309
JBrowse link
G Fmr1 FMRP translational regulator 1 decreases expression ISO Bortezomib results in decreased expression of FMR1 mRNA CTD PMID:17659339 NCBI chr  X:154,684,924...154,722,369
Ensembl chr  X:154,684,935...154,722,314
JBrowse link
G Folr1 folate receptor alpha decreases expression ISO Bortezomib results in decreased expression of FOLR1 mRNA CTD PMID:20977926 NCBI chr 1:166,934,457...166,945,864
Ensembl chr 1:166,934,460...166,943,592
JBrowse link
G Foxa1 forkhead box A1 multiple interactions
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of FOXA1 mRNA
Bortezomib results in decreased expression of FOXA1 mRNA
CTD PMID:20471514, PMID:25913414 NCBI chr 6:78,516,579...78,549,669
Ensembl chr 6:78,545,804...78,549,669
JBrowse link
G Fry FRY microtubule binding protein increases expression ISO Bortezomib results in increased expression of FRY mRNA CTD PMID:20977926 NCBI chr12:5,573,729...5,822,874
Ensembl chr12:5,573,729...5,822,874
JBrowse link
G Fsd1l fibronectin type III and SPRY domain containing 1-like increases expression ISO Bortezomib results in increased expression of FSD1L mRNA CTD PMID:20977926 NCBI chr 5:70,441,075...70,517,131
Ensembl chr 5:70,441,123...70,511,659
JBrowse link
G Fzd2 frizzled class receptor 2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA CTD PMID:25522274 NCBI chr10:90,550,147...90,552,057
Ensembl chr10:90,550,147...90,552,057
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase decreases expression ISO Bortezomib results in decreased expression of G6PD mRNA CTD PMID:20977926 NCBI chr  X:156,274,800...156,293,935
Ensembl chr  X:156,274,800...156,293,926
JBrowse link
G Gabarapl1 GABA type A receptor associated protein like 1 increases expression ISO Bortezomib results in increased expression of GABARAPL1 mRNA CTD PMID:20977926 NCBI chr 4:163,293,724...163,302,866
Ensembl chr 4:163,293,724...163,302,858
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression
multiple interactions
ISO
EXP
Bortezomib results in increased expression of GADD45A mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA
CTD PMID:20830808, PMID:20977926, PMID:25522274 NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta increases expression
multiple interactions
ISO Bortezomib results in increased expression of GADD45B mRNA
Bortezomib inhibits the reaction [lipopolysaccharide A results in increased expression of GADD45B mRNA]
CTD PMID:15509775, PMID:15797874, PMID:17895889, PMID:17898295 NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma increases expression ISO Bortezomib results in increased expression of GADD45G mRNA CTD PMID:17898295 NCBI chr17:13,391,474...13,393,219
Ensembl chr17:13,391,467...13,393,243
JBrowse link
G Galnt4 polypeptide N-acetylgalactosaminyltransferase 4 increases expression ISO Bortezomib results in increased expression of GALNT4 mRNA CTD PMID:20977926 NCBI chr 7:41,305,437...41,309,621 JBrowse link
G Ganab glucosidase II alpha subunit decreases expression ISO Bortezomib results in decreased expression of GANAB mRNA CTD PMID:20977926 NCBI chr 1:225,096,558...225,116,384
Ensembl chr 1:225,096,598...225,116,378
JBrowse link
G Gas7 growth arrest specific 7 decreases expression ISO Bortezomib results in decreased expression of GAS7 mRNA CTD PMID:20977926 NCBI chr10:54,010,723...54,240,805
Ensembl chr10:54,126,486...54,236,476
JBrowse link
G Gbp2 guanylate binding protein 2 increases expression ISO Bortezomib results in increased expression of GBP2 mRNA CTD PMID:20977926 NCBI chr 2:248,276,795...248,293,784
Ensembl chr 2:248,276,709...248,293,784
JBrowse link
G Gcnt2 glucosaminyl (N-acetyl) transferase 2 (I blood group) increases expression ISO Bortezomib results in increased expression of GCNT2 mRNA CTD PMID:20977926 NCBI chr17:21,634,546...21,677,477
Ensembl chr17:21,634,551...21,739,408
JBrowse link
G Gdf15 growth differentiation factor 15 increases expression
multiple interactions
EXP
ISO
Bortezomib results in increased expression of GDF15 mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA
CTD PMID:20830808, PMID:25522274 NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
JBrowse link
G Ghr growth hormone receptor increases expression ISO Bortezomib results in increased expression of GHR mRNA CTD PMID:17895889 NCBI chr 2:53,149,225...53,413,954
Ensembl chr 2:53,150,370...53,413,638
JBrowse link
G Git1 GIT ArfGAP 1 decreases expression ISO Bortezomib results in decreased expression of GIT1 mRNA CTD PMID:20977926 NCBI chr10:62,656,000...62,664,467
Ensembl chr10:62,656,000...62,664,466
JBrowse link
G Gkap1 G kinase anchoring protein 1 increases expression ISO Bortezomib results in increased expression of GKAP1 mRNA CTD PMID:20977926 NCBI chr17:6,785,428...6,825,145
Ensembl chr17:6,785,428...6,825,144
JBrowse link
G Gla galactosidase, alpha increases expression ISO Bortezomib results in increased expression of GLA mRNA CTD PMID:20977926 NCBI chr  X:105,405,915...105,417,331
Ensembl chr  X:105,406,792...105,417,323
JBrowse link
G Gnai3 G protein subunit alpha i3 increases expression ISO Bortezomib results in increased expression of GNAI3 mRNA CTD PMID:20977926 NCBI chr 2:210,896,779...210,934,733
Ensembl chr 2:210,896,656...210,934,749
JBrowse link
G Gosr2 golgi SNAP receptor complex member 2 increases expression ISO Bortezomib results in increased expression of GOSR2 mRNA CTD PMID:20977926 NCBI chr10:91,735,772...91,756,123
Ensembl chr10:91,736,780...91,756,081
JBrowse link
G Gpank1 G patch domain and ankyrin repeats 1 increases expression ISO Bortezomib results in increased expression of GPANK1 mRNA CTD PMID:20977926 NCBI chr20:5,113,232...5,116,382
Ensembl chr20:5,113,339...5,116,382
JBrowse link
G Gpat3 glycerol-3-phosphate acyltransferase 3 increases expression ISO Bortezomib results in increased expression of GPAT3 mRNA CTD PMID:20977926 NCBI chr14:10,343,287...10,396,565
Ensembl chr14:10,343,282...10,395,047
JBrowse link
G Gpatch2l G patch domain containing 2-like increases expression ISO Bortezomib results in increased expression of GPATCH2L mRNA CTD PMID:20977926 NCBI chr 6:110,093,767...110,228,943
Ensembl chr 6:110,093,819...110,227,475
JBrowse link
G Gphn gephyrin decreases expression ISO Bortezomib results in decreased expression of GPHN mRNA CTD PMID:20977926 NCBI chr 6:101,327,874...101,859,169
Ensembl chr 6:101,532,518...101,859,164
JBrowse link
G Gpr157 G protein-coupled receptor 157 decreases expression ISO Bortezomib results in decreased expression of GPR157 mRNA CTD PMID:20977926 NCBI chr 5:167,109,691...167,125,380
Ensembl chr 5:167,109,691...167,125,380
JBrowse link
G Gpsm3 G-protein signaling modulator 3 decreases expression ISO Bortezomib results in decreased expression of GPSM3 mRNA CTD PMID:20977926 NCBI chr20:4,355,246...4,357,107
Ensembl chr20:4,355,175...4,357,107
JBrowse link
G Gsk3a glycogen synthase kinase 3 alpha multiple interactions ISO [Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3A protein modified form CTD PMID:16118318 NCBI chr 1:82,097,244...82,108,238
Ensembl chr 1:82,097,247...82,108,203
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO [Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3B protein modified form; Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein] CTD PMID:16118318, PMID:24085292 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Gspt1 G1 to S phase transition 1 decreases expression ISO Bortezomib results in decreased expression of GSPT1 mRNA CTD PMID:20977926 NCBI chr10:4,313,100...4,347,661
Ensembl chr10:4,312,863...4,446,200
JBrowse link
G Gsr glutathione-disulfide reductase increases expression ISO Bortezomib results in increased expression of GSR mRNA CTD PMID:20977926 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Gstcd glutathione S-transferase, C-terminal domain containing decreases expression ISO Bortezomib results in decreased expression of GSTCD mRNA CTD PMID:20977926 NCBI chr 2:238,109,758...238,253,326
Ensembl chr 2:238,109,490...238,253,287
JBrowse link
G Gstm4 glutathione S-transferase mu 4 decreases expression ISO Bortezomib results in decreased expression of GSTM4 mRNA CTD PMID:20977926 NCBI chr 2:210,834,013...210,839,242
Ensembl chr 2:210,833,884...210,839,295
JBrowse link
G Gtf3c2 general transcription factor IIIC subunit 2 decreases expression ISO Bortezomib results in decreased expression of GTF3C2 mRNA CTD PMID:20977926 NCBI chr 6:26,560,601...26,584,533
Ensembl chr 6:26,560,601...26,584,535
JBrowse link
G Gtpbp1 GTP binding protein 1 decreases expression ISO Bortezomib results in decreased expression of GTPBP1 mRNA CTD PMID:20977926 NCBI chr 7:120,923,274...120,947,723
Ensembl chr 7:120,923,274...120,947,723
JBrowse link
G Gzma granzyme A decreases expression ISO Bortezomib results in decreased expression of GZMA mRNA CTD PMID:20977926 NCBI chr 2:44,968,846...44,981,436
Ensembl chr 2:44,968,765...44,981,458
JBrowse link
G Gzmb granzyme B increases expression ISO Bortezomib results in increased expression of GZMB mRNA CTD PMID:20977926 NCBI chr15:35,413,862...35,417,293
Ensembl chr15:35,413,793...35,417,316
JBrowse link
G H2ax H2A.X variant histone multiple interactions
decreases phosphorylation
increases expression
ISO
EXP
[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein]; leptomycin B promotes the reaction [Bortezomib results in increased expression of H2AX protein modified form]
Bortezomib results in decreased phosphorylation of H2AX protein
Bortezomib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein]
CTD PMID:15173094, PMID:16778179, PMID:17875725, PMID:18790767, PMID:32482060 NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
JBrowse link
G H6pd hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) decreases expression ISO Bortezomib results in decreased expression of H6PD mRNA CTD PMID:20977926 NCBI chr 5:166,994,683...167,030,441
Ensembl chr 5:166,998,881...167,030,441
JBrowse link
G Hadha hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha increases expression ISO Bortezomib results in increased expression of HADHA mRNA CTD PMID:20977926 NCBI chr 6:27,589,840...27,628,921
Ensembl chr 6:27,589,657...27,629,175
JBrowse link
G Hdac10 histone deacetylase 10 decreases expression ISO Bortezomib results in decreased expression of HDAC10 mRNA CTD PMID:20977926 NCBI chr 7:130,102,335...130,109,036
Ensembl chr 7:130,102,347...130,107,437
JBrowse link
G Hdac4 histone deacetylase 4 decreases expression ISO Bortezomib results in decreased expression of HDAC4 mRNA CTD PMID:17659339 NCBI chr 9:99,052,945...99,299,715
Ensembl chr 9:99,057,089...99,299,715
JBrowse link
G Hdac6 histone deacetylase 6 decreases response to substance ISO HDAC6 results in decreased susceptibility to Bortezomib CTD PMID:16585204 NCBI chr  X:15,295,372...15,316,673
Ensembl chr  X:15,295,473...15,316,671
JBrowse link
G Hectd2 HECT domain E3 ubiquitin protein ligase 2 increases expression ISO Bortezomib results in increased expression of HECTD2 mRNA CTD PMID:20977926 NCBI chr 1:255,186,729...255,254,307
Ensembl chr 1:255,185,629...255,254,307
JBrowse link
G Hecw1 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA CTD PMID:25522274 NCBI chr17:53,229,997...53,777,474
Ensembl chr17:53,229,785...53,773,657
JBrowse link
G Hexd hexosaminidase D decreases expression ISO Bortezomib results in decreased expression of HEXD mRNA CTD PMID:20977926 NCBI chr10:110,406,431...110,425,042
Ensembl chr10:110,406,450...110,425,042
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression ISO Bortezomib results in increased expression of HIF1A protein CTD PMID:16061869 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hikeshi heat shock protein nuclear import factor multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA CTD PMID:25522274 NCBI chr 1:154,147,098...154,170,429
Ensembl chr 1:154,142,836...154,170,409
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases response to substance
increases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of HMOX1 mRNA; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in increased susceptibility to Bortezomib; abexinostat promotes the reaction [Bortezomib results in increased expression of HMOX1 mRNA]
HMOX1 protein results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of HMOX1 mRNA; Bortezomib results in increased expression of HMOX1 protein
CTD PMID:15509775, PMID:17895889, PMID:19417023, PMID:20471514, PMID:25913414 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hmox2 heme oxygenase 2 multiple interactions ISO abexinostat promotes the reaction [Bortezomib results in decreased expression of HMOX2 mRNA] CTD PMID:19417023 NCBI chr10:10,990,034...11,035,493
Ensembl chr10:10,990,034...11,035,484
JBrowse link
G Hnrnpll heterogeneous nuclear ribonucleoprotein L-like increases expression ISO Bortezomib results in increased expression of HNRNPLL mRNA CTD PMID:20977926 NCBI chr 6:2,698,983...2,729,715
Ensembl chr 6:2,699,961...2,729,394
JBrowse link
G Hoxa11 homeobox A11 decreases expression ISO Bortezomib results in decreased expression of HOXA11 mRNA CTD PMID:20977926 NCBI chr 4:82,296,888...82,301,419
Ensembl chr 4:82,298,152...82,300,503
Ensembl chr 4:82,298,152...82,300,503
JBrowse link
G Hps3 HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 decreases expression ISO Bortezomib results in decreased expression of HPS3 mRNA CTD PMID:20977926 NCBI chr 2:104,789,423...104,832,964
Ensembl chr 2:104,789,423...104,830,898
JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein] CTD PMID:22842577 NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
JBrowse link
G Hsf1 heat shock transcription factor 1 increases expression
multiple interactions
ISO Bortezomib results in increased expression of HSF1 mRNA
Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]
CTD PMID:17895889, PMID:23874968 NCBI chr 7:117,538,523...117,565,478
Ensembl chr 7:117,538,523...117,565,478
JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 increases expression
decreases expression
ISO
EXP
Bortezomib results in increased expression of HSP90AA1 mRNA
Bortezomib results in decreased expression of HSP90AA1 mRNA
CTD PMID:17895889, PMID:20471514, PMID:20830808 NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
JBrowse link
G Hsp90ab1 heat shock protein 90 alpha family class B member 1 increases expression ISO Bortezomib results in increased expression of HSP90AB1 mRNA CTD PMID:17895889 NCBI chr 9:17,817,791...17,823,163
Ensembl chr 9:17,817,721...17,823,243
JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A multiple interactions
decreases response to substance
increases expression
ISO Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]
HSPA1A protein results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of HSPA1A mRNA
CTD PMID:17895889, PMID:23874968 NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
JBrowse link
G Hspa1b heat shock protein family A (Hsp70) member 1B increases expression
affects response to substance
decreases response to substance
ISO Bortezomib results in increased expression of HSPA1B mRNA
HSPA1B protein affects the susceptibility to Bortezomib
HSPA1B protein results in decreased susceptibility to Bortezomib
CTD PMID:15509775, PMID:17895889, PMID:23874968 NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
JBrowse link
G Hspa4l heat shock protein family A (Hsp70) member 4 like increases expression EXP Bortezomib results in increased expression of HSPA4L mRNA CTD PMID:20830808 NCBI chr 2:127,625,737...127,682,864
Ensembl chr 2:127,625,683...127,677,503
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions
increases expression
decreases response to substance
ISO Bortezomib inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [geldanamycin results in increased expression of HSPA5 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; geldanamycin promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]
Bortezomib results in increased expression of HSPA5 mRNA
HSPA5 results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of HSPA5; Bortezomib results in increased expression of HSPA5 mRNA; Bortezomib results in increased expression of HSPA5 protein
CTD PMID:15141013, PMID:15509775, PMID:16024631, PMID:16357177, PMID:18641367, PMID:18723477, PMID:20110775, PMID:20546536, PMID:20977926, PMID:21762082, PMID:24291039 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Hspb1 heat shock protein family B (small) member 1 increases expression
decreases response to substance
EXP
ISO
Bortezomib results in increased expression of HSPB1 mRNA
HSPB1 protein results in decreased susceptibility to Bortezomib
CTD PMID:14559800, PMID:20830808 NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
JBrowse link
G Hsph1 heat shock protein family H (Hsp110) member 1 increases expression ISO Bortezomib results in increased expression of HSPH1 mRNA CTD PMID:17898295 NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
JBrowse link
G Htr2b 5-hydroxytryptamine receptor 2B decreases expression ISO Bortezomib results in decreased expression of HTR2B mRNA CTD PMID:20977926 NCBI chr 9:93,112,781...93,130,135
Ensembl chr 9:93,112,805...93,125,014
JBrowse link
G Htra2 HtrA serine peptidase 2 affects localization ISO Bortezomib affects the localization of HTRA2 protein CTD PMID:16024631 NCBI chr 4:113,883,671...113,886,833
Ensembl chr 4:113,883,670...113,886,994
JBrowse link
G Ibtk inhibitor of Bruton tyrosine kinase increases expression ISO Bortezomib results in increased expression of IBTK mRNA CTD PMID:20977926 NCBI chr 8:93,323,454...93,397,044
Ensembl chr 8:93,324,476...93,390,305
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ICAM1 mRNA; [romidepsin co-treated with Bortezomib] results in decreased expression of ICAM1 protein
Bortezomib results in decreased expression of ICAM1 mRNA
CTD PMID:18223231, PMID:20471514, PMID:25913414 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Ide insulin degrading enzyme increases expression ISO Bortezomib results in increased expression of IDE mRNA CTD PMID:20977926 NCBI chr 1:255,914,465...256,014,168
Ensembl chr 1:255,914,447...256,013,495
JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha decreases expression ISO Bortezomib results in decreased expression of IDH3A mRNA CTD PMID:30818834 NCBI chr 8:59,164,601...59,183,899
Ensembl chr 8:59,164,572...59,183,908
JBrowse link
G Ifi44 interferon-induced protein 44 increases expression ISO Bortezomib results in increased expression of IFI44 mRNA CTD PMID:20977926 NCBI chr 2:256,897,765...256,915,591
Ensembl chr 2:256,897,772...256,915,569
JBrowse link
G Ifng interferon gamma multiple interactions ISO [Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]] CTD PMID:30482226 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Ifrd2 interferon-related developmental regulator 2 decreases expression ISO Bortezomib results in decreased expression of IFRD2 mRNA CTD PMID:20977926 NCBI chr 8:116,343,096...116,348,318
Ensembl chr 8:116,343,096...116,348,314
JBrowse link
G Igf1r insulin-like growth factor 1 receptor increases response to substance ISO IGF1R gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
JBrowse link
G Igf2 insulin-like growth factor 2 multiple interactions
decreases response to substance
ISO Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein]
Bortezomib results in decreased susceptibility to IGF2 protein
CTD PMID:24055520 NCBI chr 1:215,828,102...215,839,081
Ensembl chr 1:215,828,102...215,846,911
JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta multiple interactions
decreases expression
ISO Bortezomib promotes the reaction [abexinostat results in decreased expression of IKBKB mRNA]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
Bortezomib results in decreased expression of IKBKB mRNA
CTD PMID:19417023, PMID:20471514, PMID:24085292 NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
JBrowse link
G Ikzf1 IKAROS family zinc finger 1 decreases expression ISO Bortezomib results in decreased expression of IKZF1 mRNA CTD PMID:20977926 NCBI chr14:91,782,281...91,867,828
Ensembl chr14:91,782,354...91,867,424
JBrowse link
G Il10 interleukin 10 affects expression ISO Bortezomib affects the expression of IL10 protein CTD PMID:19922463 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il15 interleukin 15 increases expression ISO Bortezomib results in increased expression of IL15 mRNA CTD PMID:20977926 NCBI chr19:23,542,606...23,624,366
Ensembl chr19:23,542,889...23,554,594
JBrowse link
G Il18r1 interleukin 18 receptor 1 increases expression ISO Bortezomib results in increased expression of IL18R1 mRNA CTD PMID:17895889 NCBI chr 9:47,184,404...47,217,403
Ensembl chr 9:47,185,443...47,219,175
JBrowse link
G Il1r1 interleukin 1 receptor type 1 increases expression ISO Bortezomib results in increased expression of IL1R1 mRNA CTD PMID:17895889 NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
JBrowse link
G Il23a interleukin 23 subunit alpha increases expression ISO Bortezomib results in increased expression of IL23A mRNA CTD PMID:17895889 NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
decreases expression
decreases secretion
ISO [Dexamethasone co-treated with Bortezomib] inhibits the reaction [IL6 protein results in increased expression of SOD2 mRNA]; [Dexamethasone co-treated with Bortezomib] results in decreased expression of IL6 mRNA; [Dexamethasone co-treated with Bortezomib] results in decreased secretion of IL6 protein; Bortezomib inhibits the reaction [IL6 protein results in decreased susceptibility to Dexamethasone]
Bortezomib inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; Bortezomib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein]
Bortezomib results in increased expression of IL6 mRNA
Bortezomib results in decreased expression of IL6 mRNA
Bortezomib results in decreased secretion of IL6 protein
CTD PMID:17895889, PMID:23063726, PMID:28134560 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Il7r interleukin 7 receptor increases expression
multiple interactions
ISO Bortezomib results in increased expression of IL7R mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA
CTD PMID:20471514, PMID:25522274
G Ino80b INO80 complex subunit B decreases expression ISO Bortezomib results in decreased expression of INO80B mRNA CTD PMID:20977926 NCBI chr 4:113,954,612...113,957,774
Ensembl chr 4:113,954,613...113,957,774
JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 decreases expression ISO Bortezomib results in decreased expression of IRAK1 mRNA CTD PMID:20471514 NCBI chr  X:156,716,469...156,726,367
Ensembl chr  X:156,716,604...156,725,977
JBrowse link
G Irak2 interleukin-1 receptor-associated kinase 2 increases expression ISO Bortezomib results in increased expression of IRAK2 mRNA CTD PMID:20977926 NCBI chr 4:145,594,575...145,651,066
Ensembl chr 4:145,594,575...145,651,053
JBrowse link
G Irs1 insulin receptor substrate 1 decreases degradation ISO Bortezomib results in decreased degradation of IRS1 protein CTD PMID:16227402 NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
JBrowse link
G Isca1 iron-sulfur cluster assembly 1 increases expression ISO Bortezomib results in increased expression of ISCA1 mRNA CTD PMID:20977926 NCBI chr17:5,281,727...5,294,386
Ensembl chr17:5,281,727...5,294,384
JBrowse link
G Itga6 integrin subunit alpha 6 decreases expression ISO Bortezomib results in decreased expression of ITGA6 mRNA CTD PMID:20977926 NCBI chr 3:58,442,904...58,515,124
Ensembl chr 3:58,443,101...58,515,124
JBrowse link
G Itgal integrin subunit alpha L decreases expression ISO Bortezomib results in decreased expression of ITGAL mRNA CTD PMID:20977926 NCBI chr 1:198,744,053...198,781,745
Ensembl chr 1:198,744,050...198,781,750
JBrowse link
G Itgav integrin subunit alpha V multiple interactions
increases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ITGAV mRNA
Bortezomib results in increased expression of ITGAV mRNA
CTD PMID:20471514, PMID:25913414 NCBI chr 3:71,113,269...71,205,958
Ensembl chr 3:71,114,100...71,202,411
JBrowse link
G Itgb6 integrin subunit beta 6 increases expression ISO Bortezomib results in increased expression of ITGB6 mRNA CTD PMID:20977926 NCBI chr 3:46,652,624...46,775,362
Ensembl chr 3:46,652,623...46,726,958
JBrowse link
G Jak1 Janus kinase 1 decreases expression ISO Bortezomib results in decreased expression of JAK1 mRNA CTD PMID:20977926 NCBI chr 5:119,982,503...120,091,452
Ensembl chr 5:119,982,943...120,083,904
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit decreases expression
increases expression
increases phosphorylation
multiple interactions
ISO
EXP
Bortezomib results in decreased expression of JUN mRNA
Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein
Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein; Bortezomib results in increased expression of JUN protein modified form
Bortezomib results in increased phosphorylation of JUN protein
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of JUN mRNA; [arsenic trioxide co-treated with Bortezomib] results in increased activity of JUN protein modified form; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of JUN protein]
CTD PMID:12393500, PMID:16357177, PMID:16985072, PMID:17351739, PMID:17495969, PMID:17898295, PMID:20471514, PMID:20830808, PMID:25913414 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit decreases expression ISO Bortezomib results in decreased expression of JUND mRNA CTD PMID:20977926 NCBI chr16:20,485,028...20,486,707
Ensembl chr16:20,485,029...20,486,707
JBrowse link
G Kat2b lysine acetyltransferase 2B decreases expression ISO Bortezomib results in decreased expression of KAT2B mRNA CTD PMID:20471514 NCBI chr 9:4,440,982...4,492,949 JBrowse link
G Kat6b lysine acetyltransferase 6B decreases expression ISO Bortezomib results in decreased expression of KAT6B mRNA CTD PMID:20977926 NCBI chr15:2,811,933...2,966,833
Ensembl chr15:2,813,537...2,966,576
JBrowse link
G Katnal1 katanin catalytic subunit A1 like 1 increases expression ISO Bortezomib results in increased expression of KATNAL1 mRNA CTD PMID:20977926 NCBI chr12:7,495,436...7,550,205
Ensembl chr12:7,208,850...7,271,872
Ensembl chr12:7,208,850...7,271,872
JBrowse link
G Kcmf1 potassium channel modulatory factor 1 increases expression ISO Bortezomib results in increased expression of KCMF1 mRNA CTD PMID:20977926 NCBI chr 4:100,759,526...100,783,017
Ensembl chr 4:100,759,526...100,783,750
JBrowse link
G Kctd10 potassium channel tetramerization domain containing 10 increases expression ISO Bortezomib results in increased expression of KCTD10 mRNA CTD PMID:20977926 NCBI chr12:47,992,079...48,010,531
Ensembl chr12:47,992,091...48,010,583
JBrowse link
G Kdelr1 KDEL endoplasmic reticulum protein retention receptor 1 decreases expression ISO Bortezomib results in decreased expression of KDELR1 mRNA CTD PMID:20977926 NCBI chr 1:101,859,346...101,870,232
Ensembl chr 1:101,859,346...101,870,232
JBrowse link
G Kdm4b lysine demethylase 4B decreases expression ISO Bortezomib results in decreased expression of KDM4B mRNA CTD PMID:20977926 NCBI chr 9:10,656,035...10,734,127
Ensembl chr 9:10,653,216...10,734,073
JBrowse link
G Kdm5c lysine demethylase 5C decreases expression ISO Bortezomib results in decreased expression of KDM5C mRNA CTD PMID:20977926 NCBI chr  X:22,302,664...22,349,298
Ensembl chr  X:22,302,485...22,348,627
JBrowse link
G Kdr kinase insert domain receptor multiple interactions ISO [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of KDR protein CTD PMID:16985072 NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
JBrowse link
G Kif22 kinesin family member 22 decreases expression ISO Bortezomib results in decreased expression of KIF22 mRNA CTD PMID:20977926 NCBI chr 1:198,461,406...198,476,430
Ensembl chr 1:198,461,169...198,476,476
JBrowse link
G Kif9 kinesin family member 9 decreases expression ISO Bortezomib results in decreased expression of KIF9 mRNA CTD PMID:20977926 NCBI chr 8:118,737,739...118,795,190
Ensembl chr 8:118,744,229...118,794,992
JBrowse link
G Kifc1 kinesin family member C1 decreases expression ISO Bortezomib results in decreased expression of KIFC1 mRNA CTD PMID:20977926 NCBI chr20:5,509,059...5,526,175
Ensembl chr20:5,509,059...5,526,175
JBrowse link
G Klf6 Kruppel-like factor 6 increases expression ISO Bortezomib results in increased expression of KLF6 mRNA CTD PMID:20977926 NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
JBrowse link
G Klhdc7b kelch domain containing 7B increases expression ISO Bortezomib results in increased expression of KLHDC7B mRNA CTD PMID:20977926 NCBI chr 7:130,357,589...130,359,529
Ensembl chr 7:130,357,643...130,359,448
JBrowse link
G Klhl20 kelch-like family member 20 increases expression ISO Bortezomib results in increased expression of KLHL20 mRNA CTD PMID:20977926 NCBI chr13:78,912,361...78,957,226
Ensembl chr13:78,912,361...78,957,212
JBrowse link
G Klrk1 killer cell lectin like receptor K1 decreases expression ISO Bortezomib results in decreased expression of KLRK1 mRNA CTD PMID:20977926 NCBI chr 4:163,392,652...163,403,735
Ensembl chr 4:163,393,217...163,403,653
JBrowse link
G Kmt2a lysine methyltransferase 2A multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of KMT2A mRNA CTD PMID:25913414 NCBI chr 8:49,110,407...49,185,872
Ensembl chr 8:49,114,990...49,158,971
JBrowse link
G Kpna2 karyopherin subunit alpha 2 increases expression ISO Bortezomib results in increased expression of KPNA2 mRNA CTD PMID:20977926 NCBI chr10:95,200,029...95,212,111
Ensembl chr10:95,200,030...95,212,111
JBrowse link
G Kri1 KRI1 homolog increases expression ISO Bortezomib results in increased expression of KRI1 mRNA CTD PMID:20977926 NCBI chr 8:22,301,025...22,317,049
Ensembl chr 8:22,301,498...22,315,339
JBrowse link
G Krit1 KRIT1, ankyrin repeat containing increases expression ISO Bortezomib results in increased expression of KRIT1 mRNA CTD PMID:20977926 NCBI chr 4:27,438,609...27,473,150
Ensembl chr 4:27,438,609...27,473,150
JBrowse link
G Ktn1 kinectin 1 increases expression ISO Bortezomib results in increased expression of KTN1 mRNA CTD PMID:20977926 NCBI chr15:24,465,761...24,552,833
Ensembl chr15:24,479,761...24,553,197
JBrowse link
G Lgals2 galectin 2 decreases expression ISO Bortezomib results in decreased expression of LGALS2 mRNA CTD PMID:17659339 NCBI chr 7:120,071,122...120,077,612
Ensembl chr 7:120,071,124...120,077,612
JBrowse link
G Lgals8 galectin 8 increases expression ISO Bortezomib results in increased expression of LGALS8 mRNA CTD PMID:20977926 NCBI chr17:66,487,451...66,515,316
Ensembl chr17:66,487,457...66,511,870
JBrowse link
G Lgr4 leucine-rich repeat-containing G protein-coupled receptor 4 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA CTD PMID:25522274 NCBI chr 3:101,051,960...101,152,119
Ensembl chr 3:101,051,955...101,152,119
JBrowse link
G Lig4 DNA ligase 4 increases expression ISO Bortezomib results in increased expression of LIG4 mRNA CTD PMID:20977926 NCBI chr16:85,331,771...85,339,496
Ensembl chr16:85,331,866...85,337,769
JBrowse link
G Lima1 LIM domain and actin binding 1 increases expression ISO Bortezomib results in increased expression of LIMA1 mRNA CTD PMID:20977926 NCBI chr 7:141,428,113...141,528,447
Ensembl chr 7:141,428,063...141,528,397
JBrowse link
G Limd1 LIM domains containing 1 increases expression ISO Bortezomib results in increased expression of LIMD1 mRNA CTD PMID:20977926 NCBI chr 8:132,553,218...132,598,826
Ensembl chr 8:132,553,218...132,598,812
JBrowse link
G Lims1 LIM zinc finger domain containing 1 increases expression ISO Bortezomib results in increased expression of LIMS1 mRNA CTD PMID:20977926 NCBI chr20:27,895,981...28,004,767
Ensembl chr20:27,954,433...28,002,082
JBrowse link
G Lmna lamin A/C increases cleavage ISO Bortezomib results in increased cleavage of LMNA protein CTD PMID:20110775 NCBI chr 2:187,842,884...187,863,552
Ensembl chr 2:187,842,885...187,863,516
JBrowse link
G LOC100909954 uncharacterized LOC100909954 decreases expression ISO Bortezomib results in decreased expression of C14ORF132 mRNA CTD PMID:20977926 NCBI chr 6:129,259,581...129,322,113 JBrowse link
G LOC100911664 uncharacterized LOC100911664 increases expression ISO Bortezomib results in increased expression of C6ORF62 mRNA CTD PMID:20977926 NCBI chr17:42,256,971...42,268,607
Ensembl chr17:42,257,019...42,276,797
JBrowse link
G LOC361985 similar to NICE-3 decreases expression ISO Bortezomib results in decreased expression of C1ORF43 mRNA CTD PMID:20977926 NCBI chr 2:189,400,696...189,413,614
Ensembl chr 2:189,400,696...189,413,608
JBrowse link
G LOC691807 hypothetical protein LOC691807 decreases expression ISO Bortezomib results in decreased expression of C4ORF3 mRNA CTD PMID:20977926 NCBI chr 2:227,095,487...227,097,247
Ensembl chr 2:227,095,487...227,097,246
JBrowse link
G Lrfn4 leucine rich repeat and fibronectin type III domain containing 4 decreases expression ISO Bortezomib results in decreased expression of LRFN4 mRNA CTD PMID:20977926 NCBI chr 1:219,850,037...219,855,771
Ensembl chr 1:219,850,037...219,853,329
JBrowse link
G Lrrc41 leucine rich repeat containing 41 decreases expression ISO Bortezomib results in decreased expression of LRRC41 mRNA CTD PMID:20977926 NCBI chr 5:134,927,609...134,948,530
Ensembl chr 5:134,927,609...134,948,529
JBrowse link
G Lrrfip1 LRR binding FLII interacting protein 1 increases expression ISO Bortezomib results in increased expression of LRRFIP1 mRNA CTD PMID:20977926 NCBI chr 9:98,139,484...98,268,148
Ensembl chr 9:98,190,829...98,257,735
JBrowse link
G Lsm4 LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated decreases expression ISO Bortezomib results in decreased expression of LSM4 mRNA CTD PMID:20977926 NCBI chr16:20,506,399...20,511,818
Ensembl chr16:20,506,399...20,511,818
JBrowse link
G Lst1 leukocyte specific transcript 1 decreases expression ISO Bortezomib results in decreased expression of LST1 mRNA CTD PMID:20977926 NCBI chr20:5,175,213...5,179,352
Ensembl chr20:5,176,016...5,179,263
JBrowse link
G Luc7l LUC7-like increases expression ISO Bortezomib results in increased expression of LUC7L mRNA CTD PMID:20977926 NCBI chr10:15,538,878...15,572,651
Ensembl chr10:15,538,872...15,568,638
JBrowse link
G Ly96 lymphocyte antigen 96 multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of LY96 mRNA CTD PMID:25913414 NCBI chr 5:1,972,212...1,989,448 JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein CTD PMID:15039284 NCBI chr 5:16,526,058...16,642,648
Ensembl chr 5:16,526,058...16,642,648
JBrowse link
G Maf1 MAF1 homolog, negative regulator of RNA polymerase III multiple interactions ISO Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein] CTD PMID:31645432 NCBI chr 7:117,417,643...117,420,722
Ensembl chr 7:117,417,687...117,420,719
JBrowse link
G Mafg MAF bZIP transcription factor G increases expression ISO Bortezomib results in increased expression of MAFG mRNA CTD PMID:20977926 NCBI chr10:109,802,877...109,811,476
Ensembl chr10:109,806,159...109,811,323
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein] CTD PMID:24085292 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAP2K1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein CTD PMID:12893773 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 decreases expression ISO Bortezomib results in decreased expression of MAP2K2 mRNA CTD PMID:20977926 NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
JBrowse link
G Map2k4 mitogen activated protein kinase kinase 4 multiple interactions ISO alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein CTD PMID:15039284 NCBI chr10:52,196,121...52,301,887
Ensembl chr10:52,196,124...52,290,657
JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 decreases expression ISO Bortezomib results in decreased expression of MAP2K6 mRNA CTD PMID:20977926 NCBI chr10:98,707,160...98,823,054
Ensembl chr10:98,706,960...98,823,287
JBrowse link
G Map4k3 mitogen-activated protein kinase kinase kinase kinase 3 increases expression ISO Bortezomib results in increased expression of MAP4K3 mRNA CTD PMID:20977926 NCBI chr 6:3,276,732...3,444,519
Ensembl chr 6:3,276,738...3,444,519
JBrowse link
G Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 increases expression ISO Bortezomib results in increased expression of MAP4K4 mRNA CTD PMID:20977926 NCBI chr 9:46,657,444...46,782,545
Ensembl chr 9:46,657,575...46,782,545
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases expression
increases phosphorylation
decreases activity
ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAPK1 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK1 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK1 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein]
Bortezomib results in decreased activity of MAPK1 protein
CTD PMID:12893773, PMID:15039284, PMID:18445700, PMID:19383353, PMID:20701607 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk10 mitogen activated protein kinase 10 multiple interactions ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein] CTD PMID:15173093 NCBI chr14:8,079,955...8,371,508
Ensembl chr14:8,080,275...8,368,254
JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions ISO [Bortezomib co-treated with Butyrates] results in increased phosphorylation of MAPK14 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein] CTD PMID:12893773, PMID:18790767 NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases expression
increases phosphorylation
decreases activity
ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAPK3 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK3 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK3 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein]
Bortezomib results in decreased activity of MAPK3 protein
CTD PMID:12893773, PMID:15039284, PMID:18445700, PMID:19383353, PMID:20701607 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
increases phosphorylation
ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK8 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein]; MAPK8 results in increased susceptibility to [Bortezomib co-treated with CGC 11093] CTD PMID:12893773, PMID:15039284, PMID:15173093, PMID:16985072, PMID:18559525 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 increases phosphorylation
multiple interactions
ISO Bortezomib results in increased phosphorylation of MAPK9 protein
[Bortezomib co-treated with arsenic trioxide] affects the expression of MAPK9 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK9 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK9 protein]; MAPK9 results in increased susceptibility to [Bortezomib co-treated with CGC 11093]
CTD PMID:16985072, PMID:18559525, PMID:18718063 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mapkap1 MAPK associated protein 1 decreases expression ISO Bortezomib results in decreased expression of MAPKAP1 mRNA CTD PMID:20977926 NCBI chr 3:13,484,952...13,701,772
Ensembl chr 3:13,484,838...13,701,757
JBrowse link
G Mapkapk2 MAPK activated protein kinase 2 decreases expression ISO Bortezomib results in decreased expression of MAPKAPK2 mRNA CTD PMID:20977926 NCBI chr13:47,785,157...47,871,684
Ensembl chr13:47,785,161...47,831,110
JBrowse link
G Mark2 microtubule affinity regulating kinase 2 decreases expression ISO Bortezomib results in decreased expression of MARK2 mRNA CTD PMID:20977926 NCBI chr 1:222,525,547...222,590,727
Ensembl chr 1:222,525,990...222,590,220
JBrowse link
G Maz MYC associated zinc finger protein decreases expression ISO Bortezomib results in decreased expression of MAZ mRNA CTD PMID:20977926 NCBI chr 1:198,456,699...198,460,126
Ensembl chr 1:198,456,699...198,460,126
JBrowse link
G Mbd1 methyl-CpG binding domain protein 1 decreases expression ISO Bortezomib results in decreased expression of MBD1 mRNA CTD PMID:20977926 NCBI chr18:70,248,568...70,263,190
Ensembl chr18:70,248,713...70,263,164
JBrowse link
G Mbd4 methyl-CpG binding domain 4 DNA glycosylase increases expression ISO Bortezomib results in increased expression of MBD4 mRNA CTD PMID:20977926 NCBI chr 4:147,744,673...147,756,462
Ensembl chr 4:147,746,186...147,756,294
JBrowse link
G Mbl2 mannose binding lectin 2 increases response to substance ISO MBL2 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 1:248,435,069...248,442,669
Ensembl chr 1:248,723,397...248,729,962
JBrowse link
G Mbnl1 muscleblind-like splicing regulator 1 decreases expression ISO Bortezomib results in decreased expression of MBNL1 mRNA CTD PMID:20977926 NCBI chr 2:150,698,248...150,867,791
Ensembl chr 2:150,756,185...150,869,690
JBrowse link
G Mbp myelin basic protein decreases expression ISO Bortezomib results in decreased expression of MBP mRNA CTD PMID:20977926 NCBI chr18:79,326,738...79,437,310
Ensembl chr18:79,326,738...79,437,310
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
increases expression
decreases response to substance
increases cleavage
ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein modified form; [Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; romidepsin inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of MCL1 protein]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]
Bortezomib inhibits the reaction [Acetaminophen results in decreased expression of MCL1 protein]
MCL1 protein results in decreased susceptibility to Bortezomib; MCL1 results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of MCL1; Bortezomib results in increased expression of MCL1 protein
CTD PMID:12893773, PMID:15173093, PMID:16617327, PMID:18223231, PMID:18534018, PMID:18566236, PMID:18625202, PMID:19100720, PMID:20051518, PMID:21195056, PMID:21345073, PMID:25752611, PMID:26769846 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Mcm7 minichromosome maintenance complex component 7 decreases expression ISO Bortezomib results in decreased expression of MCM7 mRNA CTD PMID:17659339 NCBI chr12:19,306,615...19,313,877
Ensembl chr12:19,306,607...19,314,016
JBrowse link
G Mdc1 mediator of DNA damage checkpoint 1 decreases expression ISO Bortezomib results in decreased expression of MDC1 mRNA CTD PMID:20977926 NCBI chr20:3,405,017...3,419,831
Ensembl chr20:3,404,711...3,419,831
JBrowse link
G Mdm2 MDM2 proto-oncogene multiple interactions
increases cleavage
affects expression
ISO [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein]
Bortezomib affects the expression of MDM2 protein
CTD PMID:12393500 NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
JBrowse link
G Me1 malic enzyme 1 increases expression ISO Bortezomib results in increased expression of ME1 mRNA CTD PMID:20977926 NCBI chr 8:94,256,830...94,368,834
Ensembl chr 8:94,256,839...94,368,834
JBrowse link
G Mettl21a methyltransferase like 21A increases expression ISO Bortezomib results in increased expression of METTL21A mRNA CTD PMID:20977926 NCBI chr 9:71,304,138...71,314,015
Ensembl chr 9:71,304,427...71,313,940
JBrowse link
G Mettl27 methyltransferase like 27 decreases expression ISO Bortezomib results in decreased expression of METTL27 mRNA CTD PMID:20977926 NCBI chr12:24,767,351...24,775,891
Ensembl chr12:24,767,351...24,775,891
JBrowse link
G Mex3d mex-3 RNA binding family member D decreases expression ISO Bortezomib results in decreased expression of MEX3D mRNA CTD PMID:20977926 NCBI chr 7:12,191,902...12,198,841
Ensembl chr 7:12,192,088...12,198,551
JBrowse link
G Mfn1 mitofusin 1 decreases expression ISO Bortezomib results in decreased expression of MFN1 mRNA CTD PMID:20977926 NCBI chr 2:118,929,738...118,971,689
Ensembl chr 2:118,929,738...118,973,698
JBrowse link
G Mfng MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase decreases expression ISO Bortezomib results in decreased expression of MFNG mRNA CTD PMID:20977926 NCBI chr 7:119,978,981...119,996,824
Ensembl chr 7:119,978,983...119,996,824
JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase multiple interactions ISO Bortezomib inhibits the reaction [Disulfiram results in increased degradation of MGMT protein] CTD PMID:24193513 NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
JBrowse link
G Mir21 microRNA 21 increases expression ISO Bortezomib results in increased expression of MIR21 mRNA CTD PMID:20977926 NCBI chr10:73,902,210...73,902,301
Ensembl chr10:73,902,210...73,902,301
JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of MKI67 protein
[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]
CTD PMID:19372569, PMID:30482226 NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
JBrowse link
G Mllt11 MLLT11, transcription factor 7 cofactor increases expression ISO Bortezomib results in increased expression of MLLT11 mRNA CTD PMID:20977926 NCBI chr 2:196,392,936...196,402,106
Ensembl chr 2:196,392,938...196,402,106
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO Bortezomib promotes the reaction [butein results in decreased expression of MMP9 protein] CTD PMID:20696233 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mob3a MOB kinase activator 3A decreases expression ISO Bortezomib results in decreased expression of MOB3A mRNA CTD PMID:17659339 NCBI chr 7:11,878,943...11,896,226
Ensembl chr 7:11,878,943...11,896,223
JBrowse link
G Morc2 MORC family CW-type zinc finger 2 increases expression ISO Bortezomib results in increased expression of MORC2 mRNA CTD PMID:20977926 NCBI chr14:83,889,138...83,930,263
Ensembl chr14:83,889,089...83,930,522
JBrowse link
G Mpz myelin protein zero decreases expression EXP
ISO
Bortezomib results in decreased expression of MPZ mRNA; Bortezomib results in decreased expression of MPZ protein CTD PMID:20830808 NCBI chr13:89,524,204...89,530,070
Ensembl chr13:89,524,329...89,530,068
JBrowse link
G Mrpl19 mitochondrial ribosomal protein L19 increases expression ISO Bortezomib results in increased expression of MRPL19 mRNA CTD PMID:20977926 NCBI chr 4:112,703,041...112,707,270
Ensembl chr 4:112,703,041...112,707,270
JBrowse link
G Mrpl30 mitochondrial ribosomal protein L30 decreases expression ISO Bortezomib results in decreased expression of MRPL30 mRNA CTD PMID:20977926 NCBI chr 9:44,483,809...44,496,116
Ensembl chr 9:44,483,875...44,571,331
JBrowse link
G Mrps12 mitochondrial ribosomal protein S12 decreases expression ISO Bortezomib results in decreased expression of MRPS12 mRNA CTD PMID:20977926 NCBI chr 1:86,920,679...86,923,626
Ensembl chr 1:86,920,680...86,923,575
JBrowse link
G Mrps5 mitochondrial ribosomal protein S5 decreases expression ISO Bortezomib results in decreased expression of MRPS5 mRNA CTD PMID:20977926 NCBI chr 3:120,165,953...120,182,536
Ensembl chr 3:120,165,913...120,182,536
JBrowse link
G Msh6 mutS homolog 6 decreases expression ISO Bortezomib results in decreased expression of MSH6 mRNA CTD PMID:17659339 NCBI chr 6:11,644,565...11,662,389
Ensembl chr 6:11,644,578...11,662,499
JBrowse link
G Mtmr6 myotubularin related protein 6 increases expression ISO Bortezomib results in increased expression of MTMR6 mRNA CTD PMID:20977926 NCBI chr15:40,558,917...40,597,311
Ensembl chr15:40,558,932...40,597,309
JBrowse link
G Muc1 mucin 1, cell surface associated decreases expression ISO Bortezomib results in decreased expression of MUC1 mRNA CTD PMID:20977926 NCBI chr 2:188,543,137...188,547,874
Ensembl chr 2:188,543,137...188,547,874
JBrowse link
G Mutyh mutY DNA glycosylase decreases expression ISO Bortezomib results in decreased expression of MUTYH mRNA CTD PMID:17659339 NCBI chr 5:135,663,328...135,675,348
Ensembl chr 5:135,663,371...135,675,344
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
increases expression
decreases expression
ISO [Bortezomib co-treated with abexinostat] results in decreased expression of MYC mRNA; Bortezomib promotes the reaction [abexinostat results in decreased expression of MYC protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein]
Bortezomib results in increased expression of MYC protein
Bortezomib results in decreased expression of MYC protein
CTD PMID:12902978, PMID:18641367, PMID:19417023, PMID:20022965 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Myd88 MYD88, innate immune signal transduction adaptor decreases expression ISO Bortezomib results in decreased expression of MYD88 mRNA CTD PMID:20471514 NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
JBrowse link
G Myl12a myosin light chain 12A increases expression ISO Bortezomib results in increased expression of MYL12A mRNA CTD PMID:20977926 NCBI chr 9:119,325,282...119,333,012
Ensembl chr 9:119,325,283...119,332,967
JBrowse link
G Myo5a myosin VA increases response to substance ISO MYO5A gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 8:82,038,966...82,156,507
Ensembl chr 8:82,037,977...82,156,617
JBrowse link
G Naa80 N(alpha)-acetyltransferase 80, NatH catalytic subunit decreases expression ISO Bortezomib results in decreased expression of NAA80 mRNA CTD PMID:17659339 NCBI chr 8:116,336,441...116,339,691
Ensembl chr 8:116,336,441...116,339,690
JBrowse link
G Nab2 Ngfi-A binding protein 2 decreases expression ISO Bortezomib results in decreased expression of NAB2 mRNA CTD PMID:20977926 NCBI chr 7:70,963,580...70,971,471
Ensembl chr 7:70,961,575...70,969,905
JBrowse link
G Nabp1 nucleic acid binding protein 1 increases expression ISO Bortezomib results in increased expression of NABP1 mRNA CTD PMID:20977926 NCBI chr 9:55,049,893...55,057,784
Ensembl chr 9:55,050,203...55,057,658
JBrowse link
G Nadk NAD kinase decreases expression ISO Bortezomib results in decreased expression of NADK mRNA CTD PMID:20977926 NCBI chr 5:172,984,930...173,015,505
Ensembl chr 5:172,986,291...173,015,494
JBrowse link
G Nadk2 NAD kinase 2, mitochondrial increases expression ISO Bortezomib results in increased expression of NADK2 mRNA CTD PMID:20977926 NCBI chr 2:58,462,588...58,504,735
Ensembl chr 2:58,462,588...58,504,728
JBrowse link
G Naf1 nuclear assembly factor 1 ribonucleoprotein increases expression ISO Bortezomib results in increased expression of NAF1 mRNA CTD PMID:20977926 NCBI chr16:24,582,000...24,612,773
Ensembl chr16:24,578,678...24,612,732
JBrowse link
G Naip6 NLR family, apoptosis inhibitory protein 6 affects expression ISO Bortezomib affects the expression of NAIP mRNA CTD PMID:25913414 NCBI chr 2:30,377,505...30,418,578 JBrowse link
G Nap1l2 nucleosome assembly protein 1-like 2 increases expression ISO Bortezomib results in increased expression of NAP1L2 mRNA CTD PMID:20977926 NCBI chr  X:73,997,274...73,999,677 JBrowse link
G Ncf4 neutrophil cytosolic factor 4 decreases expression ISO Bortezomib results in decreased expression of NCF4 mRNA CTD PMID:20977926 NCBI chr 7:119,481,711...119,499,426
Ensembl chr 7:119,482,272...119,499,425
JBrowse link
G Nckap1 NCK-associated protein 1 increases expression ISO Bortezomib results in increased expression of NCKAP1 mRNA CTD PMID:20977926 NCBI chr 3:67,725,180...67,804,680
Ensembl chr 3:67,725,947...67,787,990
JBrowse link
G Ncoa3 nuclear receptor coactivator 3 increases expression ISO Bortezomib results in increased expression of NCOA3 mRNA CTD PMID:20977926 NCBI chr 3:162,692,176...162,788,582
Ensembl chr 3:162,692,185...162,787,548
JBrowse link
G Ncr1 natural cytotoxicity triggering receptor 1 decreases expression ISO Bortezomib results in decreased expression of NCR1 protein CTD PMID:19229052 NCBI chr 1:73,178,917...73,226,504
Ensembl chr 1:73,179,013...73,226,777
JBrowse link
G Ndrg1 N-myc downstream regulated 1 increases expression ISO Bortezomib results in increased expression of NDRG1 mRNA CTD PMID:20977926 NCBI chr 7:107,734,326...107,775,701
Ensembl chr 7:107,734,323...107,775,714
JBrowse link
G Ndrg3 NDRG family member 3 decreases expression ISO Bortezomib results in decreased expression of NDRG3 mRNA CTD PMID:20977926 NCBI chr 3:152,972,055...153,099,089 JBrowse link
G Nedd1 NEDD1 gamma-tubulin ring complex targeting factor increases expression ISO Bortezomib results in increased expression of NEDD1 mRNA CTD PMID:20977926 NCBI chr 7:33,544,097...33,584,406
Ensembl chr 7:33,543,828...33,584,564
JBrowse link
G Neto2 neuropilin and tolloid like 2 decreases expression ISO Bortezomib results in decreased expression of NETO2 mRNA CTD PMID:20977926 NCBI chr19:22,450,579...22,486,530
Ensembl chr19:22,450,030...22,486,531
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 increases expression
increases activity
ISO [Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of NFE2L2 protein
Bortezomib results in increased activity of NFE2L2 protein
CTD PMID:20806931, PMID:30818834 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfia nuclear factor I/A decreases expression ISO Bortezomib results in decreased expression of NFIA mRNA CTD PMID:20977926 NCBI chr 5:116,421,895...116,750,381
Ensembl chr 5:116,420,690...116,751,416
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions
decreases expression
ISO [Bortezomib co-treated with vorinostat] results in decreased activity of [NFKB1 protein binds to RELA protein]; [resveratrol co-treated with Bortezomib] results in decreased activity of [RELA protein binds to NFKB1 protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKB1 protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKB1 protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]]
Bortezomib results in decreased expression of NFKB1 mRNA; Bortezomib results in decreased expression of NFKB1 protein
CTD PMID:12893773, PMID:16230421, PMID:17164350, PMID:17626072, PMID:18223231, PMID:25913414 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkb2 nuclear factor kappa B subunit 2 decreases cleavage
decreases expression
ISO Bortezomib results in decreased cleavage of NFKB2 protein
Bortezomib results in decreased expression of NFKB2 mRNA; Bortezomib results in decreased expression of NFKB2 protein
CTD PMID:17626072, PMID:18223231, PMID:25913414 NCBI chr 1:266,050,634...266,059,277
Ensembl chr 1:266,053,002...266,059,256
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions
increases phosphorylation
increases stability
increases degradation
increases expression
decreases degradation
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of NFKBIA protein; [Bortezomib co-treated with TNFSF10 protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; [Dexamethasone co-treated with Bortezomib] results in increased expression of NFKBIA mRNA; [Dexamethasone co-treated with Bortezomib] results in increased phosphorylation of NFKBIA protein; alvocidib promotes the reaction [Bortezomib results in increased expression of NFKBIA protein modified form]; Ammonium Chloride inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKBIA protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKBIA protein]; Bortezomib promotes the reaction [alvocidib results in increased expression of NFKBIA protein modified form]; Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Chloroquine inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Dexamethasone inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; NFKBIA protein mutant form inhibits the reaction [Bortezomib results in increased expression of PTGS2 protein]; SC 514 affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; SC 514 inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]
Bortezomib results in increased stability of NFKBIA protein
Bortezomib results in increased expression of NFKBIA mRNA; Bortezomib results in increased expression of NFKBIA protein modified form
Bortezomib results in decreased degradation of NFKBIA protein
CTD PMID:15039284, PMID:15543232, PMID:17895889, PMID:18089816, PMID:18223231, PMID:18718063, PMID:19261616, PMID:23063726, PMID:24085292 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nfkbib NFKB inhibitor beta increases stability
increases expression
ISO Bortezomib results in increased stability of NFKBIB protein
Bortezomib results in increased expression of NFKBIB mRNA
CTD PMID:15543232, PMID:20977926, PMID:25913414 NCBI chr 1:86,941,073...86,948,845
Ensembl chr 1:86,941,074...86,948,845
JBrowse link
G Nfkbie NFKB inhibitor epsilon multiple interactions
increases stability
ISO Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of NFKBIE mRNA]
Bortezomib results in increased stability of NFKBIE protein
CTD PMID:15543232, PMID:20471514 NCBI chr 9:17,828,405...17,835,240
Ensembl chr 9:17,828,408...17,835,240
JBrowse link
G Nfyc nuclear transcription factor Y subunit gamma decreases expression ISO Bortezomib results in decreased expression of NFYC mRNA CTD PMID:20977926 NCBI chr 5:139,687,442...139,760,154
Ensembl chr 5:139,687,448...139,749,050
JBrowse link
G Nipsnap1 nipsnap homolog 1 decreases expression ISO Bortezomib results in decreased expression of NIPSNAP1 mRNA CTD PMID:20977926 NCBI chr14:85,113,578...85,137,457
Ensembl chr14:85,113,578...85,137,454
JBrowse link
G Nlrp12 NLR family, pyrin domain containing 12 multiple interactions
increases expression
ISO Bortezomib promotes the reaction [arsenic trioxide results in increased expression of NLRP12 mRNA]
Bortezomib results in increased expression of NLRP12 mRNA
CTD PMID:20471514 NCBI chr 1:64,506,750...64,543,908
Ensembl chr 1:64,506,735...64,534,912
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 decreases expression ISO Bortezomib results in decreased expression of NLRP3 mRNA CTD PMID:17659339 NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
JBrowse link
G Nos1 nitric oxide synthase 1 increases expression
multiple interactions
ISO Bortezomib results in increased expression of NOS1 protein
betulinic acid inhibits the reaction [Bortezomib results in increased expression of NOS1 protein]
CTD PMID:30482226 NCBI chr12:44,214,949...44,405,530
Ensembl chr12:44,213,943...44,520,341
JBrowse link
G Notch2 notch receptor 2 decreases expression ISO Bortezomib results in decreased expression of NOTCH2 mRNA CTD PMID:20977926 NCBI chr 2:200,187,184...200,320,403
Ensembl chr 2:200,187,179...200,320,215
JBrowse link
G Npm1 nucleophosmin 1 multiple interactions
affects response to substance
increases response to substance
ISO Acetylcysteine inhibits the reaction [NPM1 protein mutant form results in increased susceptibility to Bortezomib]
NPM1 protein affects the susceptibility to Bortezomib
CTD PMID:23877794 NCBI chr10:18,080,949...18,091,062
Ensembl chr10:18,080,950...18,090,950
JBrowse link
G Nptx1 neuronal pentraxin 1 decreases expression ISO Bortezomib results in decreased expression of NPTX1 mRNA CTD PMID:20977926 NCBI chr10:108,682,637...108,691,592
Ensembl chr10:108,682,638...108,691,367
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO Bortezomib results in increased expression of NQO1 mRNA CTD PMID:20977926 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone reductase 2 increases expression ISO Bortezomib results in increased expression of NQO2 mRNA CTD PMID:20977926 NCBI chr17:32,131,847...32,158,559
Ensembl chr17:32,132,347...32,158,538
JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 decreases expression ISO Bortezomib results in decreased expression of NR1H3 mRNA CTD PMID:20977926 NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO Bortezomib inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] CTD PMID:25257666 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO Bortezomib inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein] CTD PMID:30818834 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Nrip3 nuclear receptor interacting protein 3 increases expression EXP Bortezomib results in increased expression of NRIP3 mRNA CTD PMID:20830808 NCBI chr 1:174,385,424...174,411,141
Ensembl chr 1:174,385,424...174,411,141
JBrowse link
G Nt5c2 5'-nucleotidase, cytosolic II increases expression ISO Bortezomib results in increased expression of NT5C2 mRNA CTD PMID:20977926 NCBI chr 1:266,652,966...266,782,935
Ensembl chr 1:266,659,519...266,782,910
JBrowse link
G Nt5e 5' nucleotidase, ecto decreases expression ISO Bortezomib results in decreased expression of NT5E mRNA CTD PMID:20977926 NCBI chr 8:95,969,002...96,012,733
Ensembl chr 8:95,968,652...96,012,696
JBrowse link
G Nub1 negative regulator of ubiquitin-like proteins 1 increases expression ISO Bortezomib results in increased expression of NUB1 mRNA CTD PMID:20977926 NCBI chr 4:6,950,870...6,981,400
Ensembl chr 4:6,951,478...6,978,073
JBrowse link
G Nucks1 nuclear casein kinase and cyclin-dependent kinase substrate 1 decreases expression ISO Bortezomib results in decreased expression of NUCKS1 mRNA CTD PMID:20977926 NCBI chr13:48,679,726...48,709,663
Ensembl chr13:48,679,774...48,705,575
JBrowse link
G Numb NUMB, endocytic adaptor protein increases expression ISO Bortezomib results in increased expression of NUMB mRNA CTD PMID:20977926 NCBI chr 6:107,279,917...107,325,345
Ensembl chr 6:107,279,920...107,325,345
JBrowse link
G Numbl NUMB-like, endocytic adaptor protein increases expression ISO Bortezomib results in increased expression of NUMBL mRNA CTD PMID:20977926 NCBI chr 1:84,067,841...84,091,659
Ensembl chr 1:84,067,938...84,091,671
JBrowse link
G Nupr1 nuclear protein 1, transcriptional regulator multiple interactions
increases expression
ISO NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA]
Bortezomib results in increased expression of NUPR1 mRNA
CTD PMID:20022965 NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
JBrowse link
G Nxpe3 neurexophilin and PC-esterase domain family, member 3 increases expression ISO Bortezomib results in increased expression of NXPE3 mRNA CTD PMID:20977926 NCBI chr11:47,188,332...47,238,372
Ensembl chr11:47,188,495...47,238,372
JBrowse link
G Obscn obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF decreases expression ISO Bortezomib results in decreased expression of OBSCN mRNA CTD PMID:20977926 NCBI chr10:45,353,185...45,483,570
Ensembl chr10:45,338,009...45,481,008
JBrowse link
G Ogdh oxoglutarate dehydrogenase decreases expression ISO Bortezomib results in decreased expression of OGDH mRNA CTD PMID:20977926 NCBI chr14:86,414,924...86,481,903
Ensembl chr14:86,414,949...86,613,327
JBrowse link
G Ogfr opioid growth factor receptor decreases expression ISO Bortezomib results in decreased expression of OGFR mRNA CTD PMID:20977926 NCBI chr 3:176,093,662...176,099,949
Ensembl chr 3:175,930,505...176,099,987
JBrowse link
G Ogt O-linked N-acetylglucosamine (GlcNAc) transferase decreases expression ISO Bortezomib results in decreased expression of OGT mRNA CTD PMID:20977926 NCBI chr  X:71,540,870...71,585,906
Ensembl chr  X:71,528,988...71,585,908
JBrowse link
G Orai2 ORAI calcium release-activated calcium modulator 2 decreases expression ISO Bortezomib results in decreased expression of ORAI2 mRNA CTD PMID:20977926 NCBI chr12:23,544,483...23,564,602
Ensembl chr12:23,544,287...23,564,569
JBrowse link
G Os9 OS9, endoplasmic reticulum lectin increases expression ISO Bortezomib results in increased expression of OS9 mRNA CTD PMID:20977926 NCBI chr 7:70,378,625...70,407,135
Ensembl chr 7:70,380,311...70,407,177
JBrowse link
G Osbpl2 oxysterol binding protein-like 2 increases expression ISO Bortezomib results in increased expression of OSBPL2 mRNA CTD PMID:20977926 NCBI chr 3:175,493,650...175,538,965
Ensembl chr 3:175,493,698...175,538,963
JBrowse link
G Osgin1 oxidative stress induced growth inhibitor 1 increases expression ISO
EXP
Bortezomib results in increased expression of OSGIN1 mRNA CTD PMID:20830808, PMID:20977926 NCBI chr19:52,056,808...52,085,491
Ensembl chr19:52,077,109...52,085,496
JBrowse link
G Pacsin1 protein kinase C and casein kinase substrate in neurons 1 increases expression ISO Bortezomib results in increased expression of PACSIN1 mRNA CTD PMID:20977926 NCBI chr20:7,241,248...7,286,702
Ensembl chr20:7,279,820...7,286,586
JBrowse link
G Palld palladin, cytoskeletal associated protein increases expression ISO Bortezomib results in increased expression of PALLD mRNA CTD PMID:20977926 NCBI chr16:31,865,712...31,948,168 JBrowse link
G Panx2 pannexin 2 increases expression ISO Bortezomib results in increased expression of PANX2 mRNA CTD PMID:20977926 NCBI chr 7:130,042,948...130,053,034
Ensembl chr 7:130,042,947...130,053,032
JBrowse link
G Papola poly (A) polymerase alpha decreases expression ISO Bortezomib results in decreased expression of PAPOLA mRNA CTD PMID:20977926 NCBI chr 6:129,609,068...129,662,002
Ensembl chr 6:129,609,074...129,661,531
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
increases expression
ISO [alvocidib co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [arsenic trioxide co-treated with Bortezomib] results in increased degradation of PARP1 protein; [Bortezomib co-treated with abexinostat] results in increased activity of PARP1 protein; [Bortezomib co-treated with Butyrates] results in increased degradation of PARP1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of PARP1 protein; [Bortezomib co-treated with vorinostat] results in increased degradation of PARP1 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [Curcumin co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [Dichlororibofuranosylbenzimidazole co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [RB1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]]; Bortezomib promotes the reaction [belinostat results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; Bortezomib results in increased cleavage of and results in increased activity of PARP1 protein; gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]
Bortezomib results in increased expression of PARP1 protein
CTD PMID:12893773, PMID:12902978, PMID:15039284, PMID:16617327, PMID:16904634, PMID:16985072, PMID:17156654, PMID:17326159, PMID:17495969, PMID:17510429, PMID:17659339, PMID:17898295, PMID:17898787, PMID:18223231, PMID:18723477, PMID:18790767, PMID:19261616, PMID:19372569, PMID:19417023, PMID:20110775, PMID:20383943, PMID:20461078, PMID:21195056, PMID:24291039, PMID:25522274, PMID:29384525 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Parp6 poly (ADP-ribose) polymerase family, member 6 decreases expression ISO Bortezomib results in decreased expression of PARP6 mRNA CTD PMID:20977926 NCBI chr 8:64,439,933...64,472,443
Ensembl chr 8:64,440,214...64,472,443
JBrowse link
G Patz1 POZ (BTB) and AT hook containing zinc finger 1 decreases expression ISO Bortezomib results in decreased expression of PATZ1 mRNA CTD PMID:20977926 NCBI chr14:83,509,763...83,528,898
Ensembl chr14:83,510,278...83,528,898
JBrowse link
G Pawr pro-apoptotic WT1 regulator multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA CTD PMID:25522274 NCBI chr 7:51,273,764...51,353,700
Ensembl chr 7:51,273,771...51,353,068
JBrowse link
G Pbx3 PBX homeobox 3 decreases expression ISO Bortezomib results in decreased expression of PBX3 mRNA CTD PMID:20977926 NCBI chr 3:13,241,031...13,436,084
Ensembl chr 3:13,182,024...13,525,983
JBrowse link
G Pcgf3 polycomb group ring finger 3 increases expression ISO Bortezomib results in increased expression of PCGF3 mRNA CTD PMID:20977926 NCBI chr14:2,247,805...2,297,155
Ensembl chr14:2,247,808...2,297,155
JBrowse link
G Pcnx4 pecanex 4 increases expression ISO Bortezomib results in increased expression of PCNX4 mRNA CTD PMID:20977926 NCBI chr 6:95,314,867...95,452,631 JBrowse link
G Pcyt1a phosphate cytidylyltransferase 1, choline, alpha increases expression
multiple interactions
ISO Bortezomib results in increased expression of PCYT1A mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA
CTD PMID:20977926, PMID:25522274 NCBI chr11:71,547,865...71,592,037
Ensembl chr11:71,548,222...71,591,502
JBrowse link
G Pdcl phosducin-like increases expression ISO Bortezomib results in increased expression of PDCL mRNA CTD PMID:20977926 NCBI chr 3:21,602,349...21,609,821
Ensembl chr 3:21,601,816...21,609,853
JBrowse link
G Pde7a phosphodiesterase 7A decreases expression ISO Bortezomib results in decreased expression of PDE7A mRNA CTD PMID:20977926 NCBI chr 2:104,042,124...104,134,101
Ensembl chr 2:104,045,811...104,134,101
JBrowse link
G Pdgfrb platelet derived growth factor receptor beta multiple interactions ISO [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of PDGFRB protein CTD PMID:16985072 NCBI chr18:56,364,586...56,406,381
Ensembl chr18:56,364,620...56,406,381
JBrowse link
G Pdk2 pyruvate dehydrogenase kinase 2 decreases expression ISO Bortezomib results in decreased expression of PDK2 mRNA CTD PMID:20977926 NCBI chr10:82,838,270...82,852,758
Ensembl chr10:82,839,153...82,852,660
JBrowse link
G Pfdn4 prefoldin subunit 4 increases expression ISO Bortezomib results in increased expression of PFDN4 mRNA CTD PMID:20977926 NCBI chr 3:168,124,634...168,132,739
Ensembl chr 3:168,124,673...168,132,786
JBrowse link
G Pgr progesterone receptor multiple interactions ISO Bortezomib binds to and results in decreased activity of PGR protein; Bortezomib inhibits the reaction [Promegestone results in increased activity of PGR protein] CTD PMID:25752796, PMID:30818834 NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
JBrowse link
G Phc3 polyhomeotic homolog 3 increases expression ISO Bortezomib results in increased expression of PHC3 mRNA CTD PMID:20977926 NCBI chr 2:116,028,735...116,103,227
Ensembl chr 2:116,028,781...116,096,045
JBrowse link
G Phf1 PHD finger protein 1 increases expression ISO Bortezomib results in increased expression of PHF1 mRNA CTD PMID:20977926 NCBI chr20:5,526,926...5,531,940
Ensembl chr20:5,526,961...5,531,941
JBrowse link
G Phkb phosphorylase kinase regulatory subunit beta increases expression ISO Bortezomib results in increased expression of PHKB mRNA CTD PMID:20977926 NCBI chr19:22,031,684...22,281,788
Ensembl chr19:22,033,228...22,281,778
JBrowse link
G Phlda1 pleckstrin homology-like domain, family A, member 1 increases expression ISO Bortezomib results in increased expression of PHLDA1 mRNA CTD PMID:20977926 NCBI chr 7:54,247,460...54,249,664
Ensembl chr 7:54,247,460...54,249,664
JBrowse link
G Phtf1 putative homeodomain transcription factor 1 increases expression ISO Bortezomib results in increased expression of PHTF1 mRNA CTD PMID:20977926 NCBI chr 2:206,452,115...206,518,387
Ensembl chr 2:206,454,208...206,493,030
JBrowse link
G Pi4kb phosphatidylinositol 4-kinase beta decreases expression ISO Bortezomib results in decreased expression of PI4KB mRNA CTD PMID:20977926 NCBI chr 2:196,139,724...196,172,055
Ensembl chr 2:196,139,755...196,171,713
JBrowse link
G Pip4p1 phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1 decreases expression ISO Bortezomib results in decreased expression of PIP4P1 mRNA CTD PMID:20977926 NCBI chr15:27,852,152...27,855,999
Ensembl chr15:27,852,154...27,855,999
JBrowse link
G Pip5k1a phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha decreases expression ISO Bortezomib results in decreased expression of PIP5K1A mRNA CTD PMID:20977926 NCBI chr 2:196,227,669...196,270,949
Ensembl chr 2:196,227,670...196,270,826
JBrowse link
G Pir pirin increases expression ISO Bortezomib results in increased expression of PIR mRNA CTD PMID:20977926 NCBI chr  X:31,852,322...31,968,152
Ensembl chr  X:31,852,323...31,968,152
JBrowse link
G Pkia cAMP-dependent protein kinase inhibitor alpha increases expression ISO Bortezomib results in increased expression of PKIA mRNA CTD PMID:20977926 NCBI chr 2:96,593,185...96,668,222
Ensembl chr 2:96,595,088...96,668,222
JBrowse link
G Plaa phospholipase A2, activating protein increases expression ISO Bortezomib results in increased expression of PLAA mRNA CTD PMID:20977926 NCBI chr 5:113,548,913...113,578,928
Ensembl chr 5:113,548,913...113,578,928
JBrowse link
G Plekhm2 pleckstrin homology and RUN domain containing M2 decreases expression ISO Bortezomib results in decreased expression of PLEKHM2 mRNA CTD PMID:20977926 NCBI chr 5:160,182,556...160,219,770
Ensembl chr 5:160,182,251...160,219,812
JBrowse link
G Pm20d2 peptidase M20 domain containing 2 increases expression ISO Bortezomib results in increased expression of PM20D2 mRNA CTD PMID:20977926 NCBI chr 5:48,416,005...48,437,054
Ensembl chr 5:48,420,302...48,436,531
JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 multiple interactions
increases response to substance
increases expression
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of PMAIP1 mRNA; [Bortezomib co-treated with arsenic trioxide] results in increased expression of PMAIP1 protein; [Bortezomib co-treated with vorinostat] results in increased expression of PMAIP1 protein; [nutlin 3 co-treated with Bortezomib] results in increased expression of PMAIP1 protein; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with arsenic trioxide] results in increased activity of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]
PMAIP1 protein results in increased susceptibility to Bortezomib; PMAIP1 results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of PMAIP1 mRNA; Bortezomib results in increased expression of PMAIP1 protein
Bortezomib results in decreased expression of PMAIP1 mRNA
CTD PMID:16024631, PMID:16166592, PMID:16928686, PMID:17898295, PMID:18534018, PMID:18641367, PMID:18790767, PMID:20022965, PMID:20051518, PMID:20850924, PMID:20977926, PMID:21518486, PMID:25913414 NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
JBrowse link
G Pnisr PNN interacting serine and arginine rich protein increases expression ISO Bortezomib results in increased expression of PNISR mRNA CTD PMID:20977926 NCBI chr 5:35,991,028...36,017,952
Ensembl chr 5:35,991,068...36,017,944
JBrowse link
G Pnmt phenylethanolamine-N-methyltransferase decreases expression ISO Bortezomib results in decreased expression of PNMT mRNA CTD PMID:20977926 NCBI chr10:86,340,893...86,342,501
Ensembl chr10:86,340,940...86,342,858
JBrowse link
G Pno1 partner of NOB1 homolog increases expression ISO Bortezomib results in increased expression of PNO1 mRNA CTD PMID:20977926 NCBI chr14:100,364,192...100,372,760
Ensembl chr14:100,364,190...100,372,760
JBrowse link
G Poc1b POC1 centriolar protein B increases expression ISO Bortezomib results in increased expression of POC1B mRNA CTD PMID:20977926 NCBI chr 7:41,304,119...41,404,360
Ensembl chr 7:41,304,440...41,404,370
JBrowse link
G Polm DNA polymerase mu decreases expression ISO Bortezomib results in decreased expression of POLM mRNA CTD PMID:20977926 NCBI chr14:86,069,378...86,079,327
Ensembl chr14:86,069,016...86,078,954
JBrowse link
G Polr2a RNA polymerase II subunit A multiple interactions ISO Bortezomib promotes the reaction [alvocidib results in decreased phosphorylation of POLR2A protein]; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased phosphorylation of POLR2A protein] CTD PMID:15039284 NCBI chr10:56,339,277...56,364,888
Ensembl chr10:56,339,284...56,365,084
JBrowse link
G Polr3e RNA polymerase III subunit E increases expression ISO Bortezomib results in increased expression of POLR3E mRNA CTD PMID:20977926 NCBI chr 1:190,852,954...190,881,539
Ensembl chr 1:190,852,985...190,881,108
JBrowse link
G Polr3h RNA polymerase III subunit H decreases expression ISO Bortezomib results in decreased expression of POLR3H mRNA CTD PMID:20977926 NCBI chr 7:123,146,248...123,156,558
Ensembl chr 7:123,146,249...123,156,558
JBrowse link
G Ppard peroxisome proliferator-activated receptor delta increases response to substance ISO PPARD gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions ISO Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] CTD PMID:30818834 NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
JBrowse link
G Ppm1a protein phosphatase, Mg2+/Mn2+ dependent, 1A increases expression ISO Bortezomib results in increased expression of PPM1A mRNA CTD PMID:20977926 NCBI chr 6:94,433,658...94,484,979
Ensembl chr 6:94,429,068...94,484,351
JBrowse link
G Ppm1f protein phosphatase, Mg2+/Mn2+ dependent, 1F increases expression ISO Bortezomib results in increased expression of PPM1F mRNA CTD PMID:20977926 NCBI chr11:88,313,709...88,343,726
Ensembl chr11:88,313,709...88,343,627
JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A increases expression ISO Bortezomib results in increased expression of PPP1R15A mRNA; Bortezomib results in increased expression of PPP1R15A protein CTD PMID:15509775, PMID:20022965 NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
JBrowse link
G Ppp2r2a protein phosphatase 2, regulatory subunit B, alpha increases expression ISO Bortezomib results in increased expression of PPP2R2A mRNA CTD PMID:20977926 NCBI chr15:43,673,958...43,733,182
Ensembl chr15:43,673,960...43,733,182
JBrowse link
G Ppp2r5d protein phosphatase 2, regulatory subunit B', delta decreases expression ISO Bortezomib results in decreased expression of PPP2R5D mRNA CTD PMID:20977926 NCBI chr 9:16,580,995...16,610,425
Ensembl chr 9:16,586,803...16,609,631
JBrowse link
G Ppp3r1 protein phosphatase 3, regulatory subunit B, alpha decreases expression ISO Bortezomib results in decreased expression of PPP3R1 mRNA CTD PMID:20977926 NCBI chr14:100,311,224...100,360,879
Ensembl chr14:100,311,173...100,360,879
JBrowse link
G Ppp5c protein phosphatase 5, catalytic subunit decreases expression ISO Bortezomib results in decreased expression of PPP5C mRNA CTD PMID:20977926 NCBI chr 1:78,944,054...78,968,361
Ensembl chr 1:78,944,040...78,968,329
JBrowse link
G Prdm2 PR/SET domain 2 decreases expression ISO Bortezomib results in decreased expression of PRDM2 mRNA CTD PMID:20977926 NCBI chr 5:161,769,587...161,879,150
Ensembl chr 5:161,770,653...161,879,133
JBrowse link
G Prf1 perforin 1 decreases expression ISO Bortezomib results in decreased expression of PRF1 mRNA CTD PMID:20977926 NCBI chr20:30,915,294...30,920,804
Ensembl chr20:30,915,213...30,921,382
JBrowse link
G Prkcd protein kinase C, delta multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in increased cleavage of and results in increased activity of PRKCD protein; Bortezomib promotes the reaction [NSC606985 results in increased activity of and results in increased cleavage of PRKCD protein] CTD PMID:17495969, PMID:19662097 NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
JBrowse link
G Prkdc protein kinase, DNA-activated, catalytic subunit multiple interactions
increases cleavage
decreases expression
ISO [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of PRKDC protein]
Bortezomib results in decreased expression of PRKDC mRNA
CTD PMID:12393500, PMID:20977926 NCBI chr11:89,293,547...89,510,948
Ensembl chr11:89,293,696...89,510,871
JBrowse link
G Prnp prion protein increases expression ISO Bortezomib results in increased expression of PRNP mRNA CTD PMID:20977926 NCBI chr 3:124,515,917...124,531,320
Ensembl chr 3:124,515,978...124,531,316
JBrowse link
G Prpf6 pre-mRNA processing factor 6 decreases expression ISO Bortezomib results in decreased expression of PRPF6 mRNA CTD PMID:20977926 NCBI chr 3:177,098,137...177,162,937
Ensembl chr 3:177,098,073...177,162,916
JBrowse link
G Prr7 proline rich 7 (synaptic) decreases expression ISO Bortezomib results in decreased expression of PRR7 mRNA CTD PMID:20977926 NCBI chr17:9,693,274...9,702,795
Ensembl chr17:9,694,168...9,695,292
JBrowse link
G Psap prosaposin increases expression ISO Bortezomib results in increased expression of PSAP mRNA CTD PMID:20977926 NCBI chr20:29,831,302...29,856,876
Ensembl chr20:29,831,314...29,856,875
JBrowse link
G Psen1 presenilin 1 decreases expression ISO Bortezomib results in decreased expression of PSEN1 mRNA CTD PMID:20977926 NCBI chr 6:107,169,514...107,221,000
Ensembl chr 6:107,169,528...107,216,798
JBrowse link
G Psmb5 proteasome 20S subunit beta 5 affects binding
affects response to substance
increases expression
decreases response to substance
ISO
EXP
Bortezomib binds to PSMB5 protein
PSMB5 protein affects the susceptibility to Bortezomib
Bortezomib results in increased expression of PSMB5 mRNA
PSMB5 gene mutant form results in decreased susceptibility to Bortezomib
CTD PMID:20213465, PMID:22216088 NCBI chr15:33,259,039...33,263,634
Ensembl chr15:33,259,043...33,263,659
JBrowse link
G Psmc4 proteasome 26S subunit, ATPase 4 increases expression ISO Bortezomib results in increased expression of PSMC4 mRNA CTD PMID:20977926 NCBI chr 1:84,978,220...84,986,536
Ensembl chr 1:84,978,206...84,986,581
JBrowse link
G Psmd12 proteasome 26S subunit, non-ATPase 12 increases expression ISO Bortezomib results in increased expression of PSMD12 mRNA CTD PMID:20977926 NCBI chr10:95,706,808...95,725,452
Ensembl chr10:95,706,685...95,725,812
JBrowse link
G Psmd13 proteasome 26S subunit, non-ATPase 13 increases expression ISO Bortezomib results in increased expression of PSMD13 mRNA CTD PMID:20977926 NCBI chr 1:213,636,159...213,648,499
Ensembl chr 1:213,636,093...213,648,488
JBrowse link
G Psmd7 proteasome 26S subunit, non-ATPase 7 increases expression ISO Bortezomib results in increased expression of PSMD7 mRNA CTD PMID:20977926 NCBI chr19:39,639,432...39,646,718
Ensembl chr19:39,639,431...39,646,693
JBrowse link
G Psmf1 proteasome inhibitor subunit 1 decreases expression ISO Bortezomib results in decreased expression of PSMF1 mRNA CTD PMID:20977926 NCBI chr 3:147,238,111...147,263,275
Ensembl chr 3:147,238,114...147,263,275
JBrowse link
G Ptbp1 polypyrimidine tract binding protein 1 decreases expression ISO Bortezomib results in decreased expression of PTBP1 mRNA CTD PMID:20977926 NCBI chr 7:12,663,965...12,673,723
Ensembl chr 7:12,663,965...12,673,718
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Bortezomib results in increased expression of PTGS2 mRNA; Bortezomib results in increased expression of PTGS2 protein
NFKBIA protein mutant form inhibits the reaction [Bortezomib results in increased expression of PTGS2 protein]
CTD PMID:21215737, PMID:24085292 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Pthlh parathyroid hormone-like hormone decreases expression ISO Bortezomib results in decreased expression of PTHLH mRNA CTD PMID:18089816 NCBI chr 4:181,663,425...181,674,181 JBrowse link
G Ptp4a3 protein tyrosine phosphatase 4A3 decreases expression ISO Bortezomib results in decreased expression of PTP4A3 mRNA CTD PMID:20977926 NCBI chr 7:114,969,699...115,002,902
Ensembl chr 7:114,997,103...115,002,902
JBrowse link
G Ptpn11 protein tyrosine phosphatase, non-receptor type 11 decreases expression ISO Bortezomib results in decreased expression of PTPN11 mRNA CTD PMID:20977926 NCBI chr12:40,895,515...40,955,999
Ensembl chr12:40,895,515...40,955,999
JBrowse link
G Ptpn6 protein tyrosine phosphatase, non-receptor type 6 decreases expression ISO Bortezomib results in decreased expression of PTPN6 mRNA CTD PMID:17659339 NCBI chr 4:157,239,141...157,263,890
Ensembl chr 4:157,239,142...157,263,890
JBrowse link
G Ptx3 pentraxin 3 decreases expression ISO Bortezomib results in decreased expression of PTX3 mRNA CTD PMID:20471514 NCBI chr 2:158,097,843...158,103,653
Ensembl chr 2:158,097,843...158,103,653
JBrowse link
G R3hdm4 R3H domain containing 4 decreases expression ISO Bortezomib results in decreased expression of R3HDM4 mRNA CTD PMID:20977926 NCBI chr 7:12,611,476...12,618,586
Ensembl chr 7:12,611,468...12,618,586
JBrowse link
G Rab5a RAB5A, member RAS oncogene family decreases expression ISO Bortezomib results in decreased expression of RAB5A mRNA CTD PMID:20977926 NCBI chr 9:5,910...6,065 JBrowse link
G Rab8b RAB8B, member RAS oncogene family decreases expression ISO Bortezomib results in decreased expression of RAB8B mRNA CTD PMID:20977926 NCBI chr 8:72,641,680...72,714,646
Ensembl chr 8:72,638,003...72,714,664
JBrowse link
G Rac2 Rac family small GTPase 2 decreases expression ISO Bortezomib results in decreased expression of RAC2 mRNA CTD PMID:20977926 NCBI chr 7:119,769,708...119,797,111
Ensembl chr 7:119,783,849...119,797,098
JBrowse link
G Rad51 RAD51 recombinase decreases expression ISO Bortezomib results in decreased expression of RAD51 mRNA CTD PMID:21917757 NCBI chr 3:110,918,240...110,942,920
Ensembl chr 3:110,918,243...110,942,917
JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions
decreases expression
ISO [Bortezomib co-treated with Butyrates] results in decreased expression of RAF1 protein; [Bortezomib co-treated with panobinostat] results in decreased expression of RAF1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of RAF1 protein
Bortezomib results in decreased expression of RAF1 protein
CTD PMID:12893773, PMID:18445700 NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
JBrowse link
G Rala RAS like proto-oncogene A increases expression ISO Bortezomib results in increased expression of RALA mRNA CTD PMID:20977926 NCBI chr17:49,676,073...49,729,133
Ensembl chr17:49,714,294...49,727,664
JBrowse link
G Rapgef1 Rap guanine nucleotide exchange factor 1 decreases expression ISO Bortezomib results in decreased expression of RAPGEF1 mRNA CTD PMID:20977926 NCBI chr 3:8,189,594...8,307,077
Ensembl chr 3:8,192,575...8,304,976
JBrowse link
G Raph1 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 increases expression ISO Bortezomib results in increased expression of RAPH1 mRNA CTD PMID:20977926 NCBI chr 9:67,290,004...67,370,208
Ensembl chr 9:67,293,309...67,341,341
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
increases response to substance
ISO [Bortezomib co-treated with Butyrates] results in increased degradation of RB1 protein; [Bortezomib co-treated with vorinostat] results in increased degradation of RB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; [RB1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein] CTD PMID:12893773, PMID:25522274 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rb1cc1 RB1-inducible coiled-coil 1 increases expression ISO Bortezomib results in increased expression of RB1CC1 mRNA CTD PMID:20977926 NCBI chr 5:13,033,918...13,097,369
Ensembl chr 5:13,033,918...13,097,341
JBrowse link
G Rcan3 RCAN family member 3 decreases expression ISO Bortezomib results in decreased expression of RCAN3 mRNA CTD PMID:20977926 NCBI chr 5:153,773,461...153,790,271
Ensembl chr 5:153,773,663...153,790,157
JBrowse link
G Rdh11 retinol dehydrogenase 11 increases expression ISO Bortezomib results in increased expression of RDH11 mRNA CTD PMID:20977926 NCBI chr 6:102,356,498...102,372,618
Ensembl chr 6:102,356,492...102,372,611
JBrowse link
G Rdh13 retinol dehydrogenase 13 increases expression ISO Bortezomib results in increased expression of RDH13 mRNA CTD PMID:20977926 NCBI chr 1:72,956,017...72,983,811
Ensembl chr 1:72,956,026...72,984,350
JBrowse link
G Recql4 RecQ like helicase 4 increases expression ISO Bortezomib results in increased expression of RECQL4 mRNA CTD PMID:20977926 NCBI chr 7:117,765,892...117,773,128
Ensembl chr 7:117,763,783...117,773,134
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
decreases expression
decreases activity
ISO [Bortezomib co-treated with arsenic trioxide] results in decreased activity of RELA protein; [Bortezomib co-treated with trichostatin A] results in decreased expression of and results in decreased activity of RELA protein; [Bortezomib co-treated with trichostatin A] results in decreased expression of RELA protein; [Bortezomib co-treated with vorinostat] results in decreased activity of [NFKB1 protein binds to RELA protein]; [resveratrol co-treated with Bortezomib] results in decreased activity of [RELA protein binds to NFKB1 protein]; Bortezomib inhibits the reaction [belinostat results in increased acetylation of RELA protein]; Bortezomib inhibits the reaction [romidepsin results in increased acetylation of RELA protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of RELA protein]]
Bortezomib results in decreased expression of RELA mRNA; Bortezomib results in decreased expression of RELA protein
Bortezomib results in decreased activity of RELA protein
CTD PMID:12893773, PMID:16230421, PMID:16904634, PMID:17164350, PMID:17626072, PMID:18223231, PMID:18593997, PMID:20471514, PMID:20977926 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rffl ring finger and FYVE-like domain containing E3 ubiquitin protein ligase increases expression ISO Bortezomib results in increased expression of RFFL mRNA CTD PMID:20977926 NCBI chr10:70,157,621...70,220,618
Ensembl chr10:70,157,621...70,220,582
JBrowse link
G RGD1359158 similar to RIKEN cDNA 1110059E24 increases expression ISO Bortezomib results in increased expression of C9ORF85 mRNA CTD PMID:20977926 NCBI chr 1:239,207,869...239,265,997
Ensembl chr 1:239,207,869...239,265,997
JBrowse link
G RGD1560436 similar to hypothetical protein FLJ20508 increases expression ISO Bortezomib results in increased expression of C1ORF109 mRNA CTD PMID:20977926 NCBI chr 5:142,933,619...142,940,807
Ensembl chr 5:142,933,619...142,938,925
JBrowse link
G RGD1561113 similar to Hypothetical UPF0184 protein C9orf16 homolog decreases expression ISO Bortezomib results in decreased expression of C9ORF16 mRNA CTD PMID:20977926 NCBI chr 3:11,408,076...11,410,907
Ensembl chr 3:11,408,348...11,410,732
JBrowse link
G Rhobtb2 Rho-related BTB domain containing 2 increases response to substance ISO RHOBTB2 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr15:51,465,148...51,485,562
Ensembl chr15:51,465,148...51,485,692
JBrowse link
G Rhot2 ras homolog family member T2 decreases expression ISO Bortezomib results in decreased expression of RHOT2 mRNA CTD PMID:20977926 NCBI chr10:15,205,943...15,211,739
Ensembl chr10:15,205,534...15,211,325
JBrowse link
G Ripk1 receptor interacting serine/threonine kinase 1 decreases expression
increases expression
ISO Bortezomib results in decreased expression of RIPK1 mRNA
Bortezomib results in increased expression of RIPK1 protein
CTD PMID:20471514, PMID:26769846 NCBI chr17:31,537,580...31,569,904
Ensembl chr17:31,537,591...31,569,904
JBrowse link
G Ripk3 receptor-interacting serine-threonine kinase 3 increases expression ISO Bortezomib results in increased expression of RIPK3 protein CTD PMID:26769846 NCBI chr15:34,470,796...34,479,741
Ensembl chr15:34,470,796...34,479,741
JBrowse link
G Rit1 Ras-like without CAAX 1 increases expression ISO Bortezomib results in increased expression of RIT1 mRNA CTD PMID:20977926 NCBI chr 2:188,087,486...188,099,444
Ensembl chr 2:188,087,486...188,099,444
JBrowse link
G Rnd3 Rho family GTPase 3 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA CTD PMID:25522274 NCBI chr 3:36,643,374...36,660,727
Ensembl chr 3:36,642,587...36,660,758
JBrowse link
G Rnf11 ring finger protein 11 increases expression ISO Bortezomib results in increased expression of RNF11 mRNA CTD PMID:20977926 NCBI chr 5:129,296,271...129,298,513 JBrowse link
G Rnf138 ring finger protein 138 increases expression ISO Bortezomib results in increased expression of RNF138 mRNA CTD PMID:20977926 NCBI chr18:15,146,925...15,167,361 JBrowse link
G Rnf14 ring finger protein 14 increases expression ISO Bortezomib results in increased expression of RNF14 mRNA CTD PMID:20977926 NCBI chr18:31,443,424...31,468,641
Ensembl chr18:31,444,472...31,468,640
JBrowse link
G Rnf2 ring finger protein 2 increases expression ISO Bortezomib results in increased expression of RNF2 mRNA CTD PMID:20977926 NCBI chr13:68,829,714...68,859,920
Ensembl chr13:68,830,620...68,858,809
JBrowse link
G Rpa3 replication protein A3 decreases expression ISO Bortezomib results in decreased expression of RPA3 mRNA CTD PMID:17659339 NCBI chr 4:34,279,320...34,282,351
Ensembl chr 4:34,279,320...34,282,351
JBrowse link
G Rpap3 RNA polymerase II associated protein 3 increases expression ISO Bortezomib results in increased expression of RPAP3 mRNA CTD PMID:20977926 NCBI chr 7:139,167,302...139,196,468
Ensembl chr 7:139,167,303...139,196,416
JBrowse link
G Rpl26 ribosomal protein L26 increases expression ISO Bortezomib results in increased expression of RPL26 mRNA CTD PMID:20977926 NCBI chr10:55,492,417...55,495,547
Ensembl chr10:55,492,404...55,496,012
JBrowse link
G Rps11 ribosomal protein S11 increases expression ISO Bortezomib results in increased expression of RPS11 mRNA CTD PMID:20977926 NCBI chr 1:101,116,641...101,118,749
Ensembl chr 1:101,116,635...101,118,825
JBrowse link
G Rps19 ribosomal protein S19 increases expression ISO Bortezomib results in increased expression of RPS19 mRNA CTD PMID:15509775 NCBI chr 1:81,750,873...81,756,629
Ensembl chr 1:81,750,928...81,756,627
JBrowse link
G Rps6 ribosomal protein S6 increases expression ISO Bortezomib results in increased expression of RPS6 protein modified form CTD PMID:29384525 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 increases expression ISO Bortezomib results in increased expression of RPS6KB1 mRNA CTD PMID:20977926 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Rps6kc1 ribosomal protein S6 kinase C1 increases expression ISO Bortezomib results in increased expression of RPS6KC1 mRNA CTD PMID:20977926 NCBI chr13:109,338,761...109,589,209
Ensembl chr13:109,338,762...109,483,891
JBrowse link
G Rrm2b ribonucleotide reductase regulatory TP53 inducible subunit M2B increases expression ISO Bortezomib results in increased expression of RRM2B mRNA CTD PMID:20977926 NCBI chr 7:76,750,045...76,780,817
Ensembl chr 7:76,750,050...76,780,817
JBrowse link
G Rsu1 Ras suppressor protein 1 increases expression ISO Bortezomib results in increased expression of RSU1 mRNA CTD PMID:20977926 NCBI chr17:80,388,477...80,577,338
Ensembl chr17:80,389,157...80,577,027
JBrowse link
G RT1-Da RT1 class II, locus Da decreases expression ISO Bortezomib results in decreased expression of HLA-DRA mRNA CTD PMID:20977926 NCBI chr20:4,127,644...4,132,616
Ensembl chr20:4,127,644...4,132,616
JBrowse link
G RT1-DMb RT1 class II, locus DMb decreases expression ISO Bortezomib results in decreased expression of HLA-DMB mRNA CTD PMID:20977926 NCBI chr20:3,945,383...3,952,838
Ensembl chr20:5,227,045...5,234,290
JBrowse link
G RT1-DOa RT1 class II, locus DOa decreases expression ISO Bortezomib results in decreased expression of HLA-DOA mRNA CTD PMID:20977926 NCBI chr20:3,889,106...3,892,360
Ensembl chr20:3,889,370...3,892,449
JBrowse link
G Safb scaffold attachment factor B decreases expression ISO Bortezomib results in decreased expression of SAFB mRNA CTD PMID:20977926 NCBI chr 9:10,450,216...10,471,174
Ensembl chr 9:10,450,205...10,471,176
JBrowse link
G Sall4 spalt-like transcription factor 4 multiple interactions ISO Bortezomib inhibits the reaction [Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein] CTD PMID:30067223 NCBI chr 3:165,520,155...165,538,176
Ensembl chr 3:165,520,392...165,537,940
JBrowse link
G Samd10 sterile alpha motif domain containing 10 decreases expression ISO Bortezomib results in decreased expression of SAMD10 mRNA CTD PMID:20977926 NCBI chr 3:177,091,467...177,095,599
Ensembl chr 3:177,091,457...177,095,597
JBrowse link
G Scd stearoyl-CoA desaturase decreases expression ISO Bortezomib results in decreased expression of SCD mRNA CTD PMID:20977926 NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
JBrowse link
G Schip1 schwannomin interacting protein 1 decreases expression ISO Bortezomib results in decreased expression of SCHIP1 mRNA CTD PMID:20977926 NCBI chr 2:172,312,290...173,087,236
Ensembl chr 2:172,312,298...172,459,165
JBrowse link
G Scpep1 serine carboxypeptidase 1 increases expression ISO Bortezomib results in increased expression of SCPEP1 mRNA CTD PMID:20977926 NCBI chr10:76,230,371...76,263,866
Ensembl chr10:76,230,373...76,263,866
JBrowse link
G Sdhc succinate dehydrogenase complex subunit C